Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site

Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site Michael Lee, Justin Barnes, Scott Vermilyea, Joyce Meints, Hector Martinez This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3982325/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 27 Jun, 2025 Read the published version in International Journal of Molecular Sciences → Version 1 posted You are reading this latest preprint version Abstract Pathological aggregation of a-synuclein (aS) is implicated in the pathogenesis of Parkinson’s disease (PD) and other a-synucleinopathies. The current view is that neuron-to-neuron spreading of aS pathology contributes to the progression of a-synucleinopathy. We used an A53T mutant human aS transgenic mouse model ( TgA53T ) to examine whether the site of pathogenic aS inoculation affects the pattern of neuropathology and whether soluble and insoluble fractions derived from crude pathogenic tissue lysates exhibit differential capacities to initiate aS pathology. To test whether the inoculation site impacts the ultimate spatial/temporal patterns of aS pathology, aS preformed fibrils (PFF), or brain homogenates from TgA53T mice with a-synucleinopathy, were injected into the cortex/striatum, brain stem, or skeletal muscle. In all cases, inoculation of pathogenic aS induced end-stage motor dysfunction within ~100 days post-inoculation (dpi). Significantly, irrespective of the inoculation sites, ultimate distribution of the aS pathology was like that seen in normally aged TgA53T mice at end-stage, indicating that the intrinsic neuronal vulnerability is a significant determinant in the induction of aS pathology, even when initiated by inoculation of pathogenic aS. Temporal analysis of brain stem injected TgA53T mice show that initial aS pathology was seen by 30 days post-inoculation and inflammatory changes occur at later stages. To determine if the aS species with differential solubility are differentially pathogenic, brain lysates from end-stage TgA53T mice were fractionated into highly soluble (S150) and insoluble (P150) fractions, as well as the endoplasmic reticulum (ER)-enriched fraction (P100). Significantly, all fractions were able to seed de novo aS pathology in vivo , when injected unilaterally into TgA53T mice with the ER fractions being most pathogenic. Our results suggest that multiple aS species from brain can initiate the development of progressive aS pathology. Biological sciences/Neuroscience/Diseases of the nervous system/Parkinson's disease Biological sciences/Neuroscience/Diseases of the nervous system/Neurodegeneration Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Parkinson’s disease (PD) is a common late-onset, progressive neurodegenerative disorder characterized by progressive degeneration of multiple neuronal populations, particularly the dopaminergic (DAergic) neurons of the substantia nigra pars compacta (SNpc), and the presence of intracellular aggregates of α-synuclein (αS) termed Lewy bodies (LBs) and neurites (LNs). While the etiology of PD is unknown in most cases, degenerating neuronal populations in PD exhibit α-synuclein (αS) abnormalities and mutations in the αS gene cause familial PD, indicating that the αS abnormalities are mechanistically linked to pathogenesis of PD and other α-synucleinopathies 1 , 2 . The temporal analysis of αS pathology in human cases 3 indicates that αS pathology in the PD brain originates in several focal sites, particularly the dorsal motor nucleus of vagus (DMV) and the anterior olfactory nucleus. With the preclinical progression of the disease, αS pathology moves anteriorly in a topographically defined manner until reaching the cortex during the symptomatic stage. This staging led to the hypothesis that αS pathology moves via cell-to-cell transmission of amyloidogenic αS species that serves as a conformational template to seed pathology. This hypothesis was also further supported by the presence of LBs in fetal dopamine neurons grafted into PD patients 4 , 5 . Cell-to-cell transmission of α-synucleinopathy has received formal experimental support from brain injection studies establishing αS spreads transynaptically in mice 6 . Currently, direct inoculation of αS pre-formed fibrils (PFFs) or tissue lysates/fractions containing αS aggregates can induce αS pathology when directly injected into the central nervous system (CNS) or peripherally 7 . However, most current studies involve the use of αS PFF derived from recombinant αS. Thus, it is unknown if the spatial-temporal pattern of αS pathology are comparable following inoculation of various pathogenic αS species to various brain regions of αS Tg models. To better understand the spreading of α-synucleinopathy, we directly compared spatial-temporal pattern of αS pathology following inoculation of pathogenic αS species into different brain regions (cortex/striatum and dorsal brain stem) and skeletal muscle of A53T mutant human αS ( TgA53T ) transgenic mice 8 . We show that all three inoculation sites lead to end-stage pathology that is indistinguishable to that observed with aging TgA53T mice, indicating that specific neuronal populations are predisposed to the effects of toxic αS species in vivo. Temporal analysis show that overt neuroinflammation occurs after onset of αS pathology, supporting the view that inflammation is not the primary driver for the initial onset and spreading of αS pathology. We also show that both the soluble and insoluble fractions from end-stage TgA53T mice can initiate pathology in younger TgA53T mice. Further, endoplasmic reticulum (ER) associated αS from the end-stage TgA53T mice induces pathology sooner than other lysates or αS PFF. Thus, multiple species of αS are capable of inducing pathology in vivo and suggest the need to separate such entities to further clarify the form of αS that is necessary to seed pathological alterations in vivo. Results Lysates from symptomatic TgA53T mice and αS PFF induce α-synucleinopathy with similar end-stage distribution. Although the intracortical/intrastriatal (IC/IS) transmission model shows the induction and spread of αS pathology in TgA53T mice 6 , studies show that injections of pathogenic αS lysates or preformed αS fibrils (PFF) in multiple areas, including the skeletal muscle, can induce widespread αS pathology over time 9 . Thus, we examined whether the inoculation site impacts the onset and spread of αS pathology in TgA53T mice. Because brain stem (BrSt) neurons are affected early by αS pathology in both human PD 10 and in the TgA53T mouse model 8 , we compared the disease produced by the IC/IS inoculation with the BrSt injections of αS PFF. We injected young, disease-free 3–6 month-old TgA53T mice (all from line G2-3 unless noted) with end-stage lysate (ESL or S3000, a crude 3000xg pooled lysate) from BrSt/Spinal Cord (SpC) of end-stage (ES) affected TgA53T mice or lysates from disease-free (asymptomatic lysate, ASL) 5–6 months old TgA53T mice (Fig. 1a-c). Immunoblot analysis (Fig. 1b) show that both ASL and ESL contain similar amount of total αS but ESL contains greater amount of pS129αS, consistent with pathology in ES TgA53T mice. Like that seen by Luk et al . (2012), the mean of survival for bilateral IC/IS injected mice was 98 ± 8.6 days post-inoculation (dpi) (Mean ± SD) (Fig. 1d, Supplemental Fig. 1). Unilateral inoculation of ESL into the BrSt resulted in earlier onset of motor dysfunction with the mean survival of 71.3 ± 18.7 dpi (Fig. 1d, S1 a ), a significantly shorter disease time course than with IC/IS dual injections. Inoculation of αS PFF into BrSt leads to mean survival time (77.4 ± 13.16 dpi, n = 5) that is like the ESL inoculation (Fig. 1d, S1 a ). All the mice injected with ASL or saline remained disease free at ~ 150 dpi (Fig. 1d) except one ASL-inoculated animal who succumbed to disease prematurely died at ~ 9 months of age, a time point where normal aged TgA53T mice start to show disease 8 . Thus, it is likely that this animal developed disease independently of the injected lysate. Biochemical analysis of the ESL inoculated animals confirms that the ESL, but not ASL, leads to αS pathology (Fig. 2a). Analysis of Triton X100-detergent soluble and insoluble fractions reveal the accumulation of insoluble high molecular weight (HMW) species of αS (Fig. 2a, asterisks) in the SpC of ESL injected mice. In the ESL injected mice, insoluble pS129αS accumulates in BrSt and SpC, corresponding to the regions most affected by αS pathology (Fig. 2a). Consistent with lack of αS pathology, pS129αS does not accumulate in ASL (Fig. 2a) or Saline (not shown) injected mice. This pattern of αS pathology is equivalent to that seen with the ES TgA53T mice that normally develop α-synucleinopathy from aging 8 . Immunohistochemical detection of pS129αS demonstrates robust staining in multiple brain tissues from IC/IS- and BrSt-injected end-stage animals (Fig. 2b). Consistent with the lack of motor phenotype, no pathological alterations are noted in ASL-inoculated mice (Fig. 2b) or saline-injected animals (data not shown). Significantly, despite the differences in the site of inoculation (IC/IS vs BrSt), the overall patterns of pathology in the ES mice were comparable to each other with most abundant pathology in the BrSt and SpC (Fig. 2b), a pattern very similar to what is seen in the TgA53T mice that naturally develop αS pathology with aging 8 . However, we noted that IC/IS injected animals exhibit more pS129αS pathology in CTX compared to BrSt injected animals (Fig. S1 b ). To determine if components of lysates other than pathogenic αS could be responsible for the distribution of the pathology, we also examined animals that were BrSt injected with αS PFF. Our results show that the pattern of pathology seen in the ESL inoculated animals is very similar to animals injected with αS PFF into BrSt (Fig. 2b, S1 b ). Moreover, the pattern of αS pathology induced by BrSt injections are also very similar to the pathology achieved in this line of mice by peripheral, intramuscular (IM) inoculation of αS PFF 9 , 11 . To determine if the prominent subcortical pathology is unique to TgA53T(G2-3) line or occurs in another line of TgA53T , we performed IC/IS injections on TgA53T(H5) , which express 50% less αS than TgA53T(G2-3) 8 , 12 . Because of lower transgene expression, injected TgA53T(H5) animals developed progressive motor phenotype later (~ 150 dpi) than the TgA53T(G2-3) (~ 100 dpi) following IC/IS injections of αS PFF. Neuropathological analysis shows that, as with TgA53T(G2-3) , αS pathology at ES mice was most abundant in BrSt/SpC region (Fig. S2). Significantly, the TgA53T(H5) animals also showed a more widespread distribution of αS pathology, including αS pathology in the hippocampus (Fig. S2 a ). In summary, in all animals inoculated with ESL or αS PFF showed most severe BrSt and SpC αS pathology, regardless of initial sites of injections. Collectively, these results indicate that in TgA53T mice, the ES distribution of αS pathology is independent of inoculation site and likely determined by factors other than local seeding by pathogenic αS. Moreover, because our Tg models show highest levels of transgene expression in the CTX 8 , 11 , 13 , relative lack of forebrain pathology is not because of insufficient transgene expression in this area. While previous studies with the IC/IS injection model show that cortical and striatal αS pathology occurs prior to BrSt or SpC 6 , we observe more prominent early subcortical pathology with the BrSt inoculation. Thus, following the BrSt inoculation, the appearance of pS129αS over time shows that initial αS pathology develops proximal to the inoculation site where αS pathology is seen in the pons by 30 dpi (Fig. 2c). By 45 dpi, regions rostral and caudal to the BrSt inoculation sites exhibits αS pathology (Fig. 2c). Thus, we propose that following BrSt injection of pathogenic αS, the pathology spreads both rostral and caudal directions but most prominent pathology occurs in subcortical regions (Fig. 2d). Analysis of IC/IS injected TgA53T(H5) animals at intermediate stage (90 dpi) shows the presence of pS129αS in the CTX but more obvious pS129αS pathology is seen in the BrSt and SpC areas (Fig. S2b). Overall, current results collectively show that regardless of the initial injection site, subcortical areas (e.g. BrSt, SpC) exhibit earliest αS pathology and culminates in most severe αS pathology at ES TgA53T mice. Neuroinflammation follows onset of α-synucleinopathy. It has been proposed that inoculation with pathogenic αS could lead to early neuroinflammation that may promote further propagation of α-synucleinopathy 14 . Thus, we examined the spatial-temporal relationship between αS pathology and neuroinflammation. First, we confirmed that at ES, animals following BrSt injection exhibit coincident αS pathology and neuroinflammation. Tissue sections from BrSt-injected animals were stained for microglia (Iba1; Fig. 3a) and astrocytes (GFAP; Fig. 3b). Based on the morphology of the cells, no obvious neuroinflammatory changes are seen in absence of significant αS pathology, such as in CTX (Fig. 3a, b ) and in animals injected with saline (not show) or ASL (Fig. 3a, b ). However, in ES animals following ESL injection, areas with significant αS pathology (BrSt, SpC) exhibit abundant microglia and astrocytes with highly activated morphology. Immunoblotting for Iba1 and GFAP reveals no change in Ctx, but a significant increase in BrSt and SpC of ESL-injected mice at ES disease (Fig. 3c, d ; Fig. S3). To better determine the spatial-temporal relationship between the onset of microglial activation and αS pathology, the sections from BrSt inoculated mice harvested at 15-, 30-, and 45-dpi that were evaluated for αS pathology (Fig, 2 c ) were stained for microglia (Iba-1) and astrocytes (GFAP) (Fig. S4). With BrSt inoculation, αS pathology is seen in the pons by 30 dpi (Fig. 2c). However, there is no obvious signs of astrocytic or microglial activation at 30- or 45-dpi (Fig. S4). Because αS pathology is still sparse at 45 dpi, we performed double immunofluorescence analysis of pS129αS with Iba1 or GFAP (Fig. 4) to determine if presence of αS pathology could be associated with local changes in inflammatory changes. Double immunofluorescence analyses show that that while αS pathology in ES mice are clearly associated with nearby reactive astrocytes and microglia, such glial responses do not accompany αS pathology at 30- or 45-dpi (Fig. 4b, c ). Similar analysis of early-stage mice following IM αS PFF injections show that initial onset of pS129αS pathology in SpC, occurring as early as 15–30 dpi, is not accompanied by obvious glial activation (Fig. S5). While other A53T Tg models show αS pathology in astrocytes 15 , 16 , we do not observe significant pS129αS in astrocytes at ES mice (Fig. 4) 17 . Collectively, our results indicate that glial activation, particularly activation of microglia, is only evident after substantial αS pathology is established. Similar pattern of initial αS pathology followed by neuroinflammation was reported with IM inoculation of M83 line 18 . Thus, while microglia and astrocytes may modulate neuronal spreading of αS pathology or neuronal survival, our results indicate that it is unlikely that the neuroinflammation is a significant factor in the initial onset of αS pathology in TgA53T model of α-synucleinopathy. Both highly soluble and insoluble fractions induce αS pathology Because αS fibrils and disease associated aggregates in TgA53T mice are detergent insoluble 9 , 13 , we tested whether the induction of αS pathology by the ESL is mediated by the insoluble αS species. The pathogenic S3000 ESL was centrifuged at 150,000x g to obtain highly soluble (supernatant, S150) and insoluble (pellet, P150) fractions (Fig. 5a). Biochemical analyses of the fractions show that very little αS is found in P150 from asymptomatic animals (Fig. 5b). Moreover, most of the pS129αS, representing the overt αS pathology, is highly enriched in the P150 fractions from the symptomatic mice (Fig. 5b). In contrast, the amount of total αS is the same in the S150 fractions, regardless of the disease state of the animal (Fig. 5b). Despite the high levels of total αS, the levels of pS129αS in S150 is lower than in the P150 with no differences between the disease state of the animal (Fig. 5b). Thus, we expected that αS pathology would be selectively induced by the P150-ESL fraction. Following BrSt injections of P150 and S150 fractions, we were surprised to find that, regardless of the solubility of the inoculated material, inoculated TgA53T mice developed motor dysfunction leading to premature death with average lifespans of 75 ± 7 dpi for P150 fraction and 88 ± 3 dpi for S150 fraction (Fig. 5c). While 2 out of 7 subjects injected with S150 did not develop disease phenotype by 150 dpi, for those animals that died prematurely, there was no differences in the average lifespan (Fig. 5c, p = 0.1397) between S150 and P150 injected groups. Histological (Fig. 5d) and biochemical (Fig. S6) analyses of ES P150- and S150-injected animals demonstrate virtually indistinguishable αS pathology both in the spatial pattern and severity of αS aggregation (compare Figs. 2 and 5, S6). Aggregation of αS occurred throughout the CNS but was most robust in the BrSt and SpC (Fig. 5d). Biochemical analysis of brain tissue also reveals accumulation detergent insoluble αS species in the insoluble fraction from BrSt and SpC (Fig. S6a) and dramatic increases in pS129αS in both BrSt and SpC (Fig. S6 b ). Finally, based on immunostaining for Iba1 and GFAP, the distribution and intensity of neuroinflammation is similar in S150- and P150-BrSt-injected animals (Fig. 5d), and is nearly identical to that observed in ESL-injected mice (see Fig. 3). Thus, by three broad metrics: survival, IHC, and biochemistry, the α-synucleinopathy and disease induced by injection of all three end-stage lysates (S3000, S150, P150) are essentially identical. Since S3000 ASL does not induce disease and there is no obvious differences between S150 from ASL and ESL on our immunoblot analysis, S150 from ESL may contain soluble pathogenic αS conformers that is SDS labile. Thus, incomplete penetrance of end-stage S150 to cause disease could be due to the possibility that toxic αS assemblies in S150 fractions are more prone to degradation following cellular uptake compared to more mature insoluble toxic αS species in P150 (Fig. 5b). As an initial test of this hypothesis, we performed dot blot analysis of P150 and S150 for αS oligomers, using FILA1 19,20 and OC antibody 21 (Fig. S7 a,b ). We previously showed that FILA1 can recognize both soluble and insoluble αS aggregates derived of TgA53T model 20 and OC antibody selectively recognizes mature fibrils 21 . Our results show that while levels of FILA1 + oligomers are similar between P150 and S150, the levels of OC + oligomers are significantly more abundant in P150 (Fig. S7 a,b ). We also subjected S150 and P150 to proteinase K treatment as more compact mature aggregates should be more resistant to proteinase K treatment. The results show that αS in P150 is more resistant to proteinase K proteolysis than αS in S150 (Fig. S7 c ). Thus, we conclude that the presence of FILA1 + oligomers/aggregates in both S150 and P150 are pathogenic. Further, more labile FILA1 + oligomers in S150 may be responsible for the partial penetrance of S150 in inducing disease. Microsomes from symptomatic TgA53T mice induce rapid α-synucleinopathy. We previously showed that α-synucleinopathy in TgA53T mice is associated with accumulation of αS oligomers/aggregates in endoplasmic reticulum (ER) and chronic ER stress contributes to neurodegeneration 13 , 20 . Analyses of TgA53T mice inoculated with S3000 ESL show that αS pathology in these mice are also associated with signs of chronic ER stress (Fig. S8), suggesting that ER stress occurs even when α-synucleinopathy is induced by exogenous inoculation of pathogenic αS. We recently showed that ER enriched microsomes from TgA53T mice, containing αS aggregates, are highly toxic to cultured neurons and aggressively induces αS aggregates and cell death in cultured neurons 22 . Thus, we examined whether the microsome fraction from symptomatic TgA53T mice can induce pathology following BrSt injection. Microsomes from pooled BrSt/SpC or CTX from the symptomatic TgA53T mice were used for BrSt injections of 3–4 mos old TgA53T mice. Analysis of the fractions show that pS129αS is enriched in microsomes (P100 or ER) from BrSt/SpC where very little pS129αS is seen in P100 from CTX (Fig. 6a). Analysis of organelle markers show that P100 fraction is also enriched in the ER marker (Grp78/BiP). Analysis of injected animals show that P100 from symptomatic TgA53T mice develop progressive motor abnormalities by ~ 50 dpi while the animals inoculated with P100 from CTX did not show any disease phenotype (Fig. 6b). Significantly, microsome-inoculation leads to onset of motor symptoms much faster than any of the other fractions tested in this study (Compare Figs. 1d,5c & 6b), indicating that microsome associated αS oligomer/aggregates are highly pathogenic in vivo . Neuropathological analysis show that the early motor deficits were indeed associated with significant αS pathology (Fig. 6c) with the pattern that is seen with other αS fractions. Collectively, these results provide in vivo confirmation of highly pathogenic nature of ER-associated αS oligomer/aggregates 20,22 . Discussion In this report, we provide a comparative analysis of αS pathology induced by inoculation of lysates from TgA53T mice. Specifically, we examined the induction of αS pathology as a function of different lysate solubility and location of inoculation. Like that reported with αS PFF models 15 , we show that regardless of inoculation site, pathogenic lysates from brains containing α-synucleinopathy lead to a remarkably consistent pattern of ES pathology in the TgA53T model. This indicates that the regional differences in the vulnerability to develop αS pathology with aging is maintained even when α-synucleinopathy is initiated by inoculation of pathogenic αS species. We also show that, in vivo , there are multiple αS species with different solubility that induces very similar αS pathologies. Following the creation of the staging hypothesis of PD pathology by Braak and colleagues 3 , series of in vitro and in vivo studies have confirmed that αS pathology can spread from an initial site of αS aggregate induction to other neurons and brain regions 7 , 23 . It is also established that lysates from murine or human tissues with αS pathology can induce early αS pathology in αS Tg mouse models 6 . Further, numerous studies have shown that injections of αS PFF into CNS or peripheral tissue can induce αS pathology in both αS Tg mice and wild type mice 7 . While studies have generally assumed that the spreading of α-synucleinopathy occurs along the interconnected networks 23 , it is notable that while human α-synucleinopathy may progress rostrally from DMV, the interconnected aspect has not been demonstrated. Further, some studies in rodents have noted deviations from the simple cell-to-cell transmission model 15 . In this regard, we also show that while progressive α-synucleinopathy is induced by inoculation with pathogenic αS species, the pattern of α-synucleinopathy following different sites of injections is remarkably consistent with BrSt and SpC neurons being more vulnerable to developing α-synucleinopathy. Our time course study also shows that at intermediate stages, independent of where pathogenic αS is injected, αS pathology is more prominent in BrSt and SpC neurons. Analysis of intermediate stage mice for coincidence of αS pathology and glial activation indicates the αS pathology occurs prior to the microglial or astrocyte activation. This result agrees with a prior study demonstrating a temporal relationship between onset of αS pathology and microglial activation following IM inoculation 18 and we have extended prior studies by showing that at even at early stages of αS pathology, there is no obvious glial activation near the αS pathology (Fig. 4, S5). Thus, while microglia may promote αS propogation 14 , 24 , inflammatory activation of glial cells that can also influence the propagation of αS pathology likely to occur at more advanced stages of αS pathology. Most in vivo studies on transmission of α-synucleinopathies have relied on αS PFFs or oligomers derived from recombinant αS as the initiating factor for pathology. Although PFF can efficiently induce pathology, the biological relevance of an in vitro aggregated recombinant αS is unclear as the structure of αS PFF could be divergent from in vivo pathology. Because toxic species of αS in human PD and in vivo models, such as the TgA53T model, are likely to be a complex mixture of various αS species 25 – 27 , characterizing the pathology induced by tissue-derived αS species will have relevance for in vivo pathogenesis of α-synucleinopathy. This view is supported by differential induction of pathology in huαS Tg models by various human brain derived lysates 28 . In TgA53T models, αS forms soluble oligomers, particularly in the ER, and increasingly aggregate to become insoluble as the disease progresses 13 , 20 . This, taken together with the fact that pathogenic αS PFF are insoluble, we initially expected that the insoluble fraction from ESL will contain most of the disease initiating activity. Thus, we expected P150, enriched in mature pS129αS containing aggregates, to aggressively induced αS pathology following inoculation. Surprisingly, the S150 from ES mice, despite being biochemically similar to the S150 from AS mice, is capable of inducing αS pathology in vivo . Although the exact nature of the soluble “toxic” species is unknown, our results indicate that S150 contains potentially pathogenic FILA1 + αS oligomers. Regardless, our results show that different species of αS with varying degrees of solubility can induce identical pattern of pathology. We also show that, consistent with the pathogenic importance of ER associated αS pathology 20 , 22 , microsomes from ES TgA53T mice are highly pathogenic in vivo. These data thus indicate that further separating soluble and insoluble αS species by size and/or subcellular localization could be a fruitful approach for identifying the elusive transmissible αS species. In summary, our study indicates that differential neuronal vulnerability contributes to patterns of α-synucleinopathy. Thus, simple spreading of αS pathology via cell-to-cell connection cannot fully account for the progression of α-synucleinopathy. Further, our evidence supports the view that multiple αS species are capable of initiating αS pathology in vivo and it will be important to fully define the disease relevance of these different pathogenic αS species. Materials and Methods Transgenic mouse lines The transgenic mouse line over-expressing A53T mutant human αS under control of the mouse prion protein promoter has been described previously ( TgA53T , line G2-3 and line H5) 8 . TgA53T(G2-3) mice used develop a progressive, fatal neurological disease at ~ 10–14 months of age and show marked αS pathology by end-stage disease. TgA53T(H5) line express less αS (~ 50%) and do not spontaneously develop pathology 8 . Young, asymptomatic mice aged 3–6 months were used for all experiments. Animals showing complete hind-limb paralysis are considered end-stage. All study methods were approved in full by the University of Minnesota Institutional Animal Care and Use Committee and were consistent with the National Institutes of Health Office of Laboratory Animal Welfare Policy. Inoculation material Lysates used for all injections were generated from tissues of TgA53T mice at either 4 months of age (asymptomatic lysate, ASL) or end-stage (end-stage lysate, ESL). BrSt and spinal cord (SpC) were combined and processed together, as both regions demonstrate robust αS pathology at end-stage 8 . Preparation of the 3000xg lysate (S3000) has been detailed previously 6 . Briefly, affected tissue previously harvested and stored at -80 ° C was sonicated in sterile saline (0.9% NaCl; 1:10 w/vol). The homogenate was centrifuged for five minutes (3000xg, 4 ° C) and the recovered supernatant was the 3000xg lysate (S3000). To obtain highly soluble (S150) and insoluble (P150) fractions, S3000 fraction was centrifuged for 45 minutes (150,000xg, 4 ° C). The resulting supernatant was termed the S150 fraction. The pellet was washed and resuspended in sterile saline by sonication (3x10s pulses) in half of the original volume ultracentrifuged and used as the P150 fraction. Endoplasmic Reticulum (ER)-enriched fractions were obtained from TgA53T mice as previously detailed 20 , 22 . Briefly, fresh tissues were homogenized in a 1:10 (wt/vol) volume of lysis buffer (250 mM sucrose, 20mM HEPES, 10mM KCl, 1.5mM MgCl 2 , 2 mM EDTA, protease-inhibitor cocktail) and centrifuged at 1,000xg. The supernatant was centrifuged at 10,000xg to pellet mitochondria and the supernatant was centrifuged at 100,000xg to obtain ER (pellet) and cytosol (supernatant). Human αS preformed fibrils (PFF) was generated from in vitro aggregation of recombinant wild type human αS monomer as previously described 9 . Human αS PFF were stored at 5 mg/ml and were sonicated and diluted to desired concentration prior to use. Inoculation of TgA53T mice All injections were performed unilaterally into the right hemisphere in TgA53T mice at 3–6 months of age. Animals were stereotaxically injected with 2.5 µg of total protein in 2.5 µl. The injections occurred at a rate of 0.1 µl per minute using a 28g needle attached via tubing to a Hamilton syringe controlled by a constant pressure syringe pump (Harvard Apparatus, Holliston, MA). The needle was kept in place for five minutes post-injection. The stereotaxic coordinates used for the injection sites were as follows: intracortical/intrastriatal (IC/IS): 2.0 mm lateral from the midline, + 0.2 mm relative to bregma, and 0.8 and 2.6 mm deep from the dura; BrSt: 0.2 mm lateral from the midline, -7.34 mm from bregma, 3.75 mm deep from the dura. Intramuscular (IM) injections of αS PFF was done as described 9 . Briefly, isoflurane anesthetized mice (~ 3.5 months old) were bilaterally injected into the bicep femoralis muscle bilaterally with 5 µg of PFF. Starting at 60 days following PFF injections, the mice were evaluated for disease onset and progression three days per week (Monday, Wednesday, Friday). Disease onset was identified by an imbalance in gait leading to a wobbling phenotype and the end-stage was characterized as complete hindlimb paralysis. Animals were euthanized at either pre-determined time points or upon complete hind-limb paralysis. Half of the brain was used for immunohistochemistry and was immediately drop-fixed in 4% paraformaldehyde and remained in fixative for at least 48 hours. The other half was dissected into gross brain regions, including the cortex and brain stem, and either snap-frozen on dry ice and stored at -80 ° C or processed immediately. Half of spinal cords collected remained in the spinal column and were drop-fixed in 4% paraformaldehyde and half were removed and frozen or processed in the same manner as the brains. Immunohistochemistry and mapping of αS pathology All fixed brains were embedded in paraffin and serially sectioned (6 µm) in the sagittal plane. Four to Six sections taken every 12th section, starting at first section from midline containing hippocampus, was processed using standard immunohistochemical (IHC) techniques for DAB (Covance) detection as previously described 8 , 9 , 11 . Sections were counterstained with hematoxylin and imaged with a Leica DM2500 microscope using Leica Application Suite v4.1 imaging software. PhosphoSerine-129 αS (pS129αS) positive inclusions/cell bodies and neurites were mapped at three lateral positions: 0.225, 1.10, and 1.525 mm from the midline using Image J/Fiji (NIH) as previously described 9 . Immunofluorescence staining Paraffin sections of sagittal brain (BrSt injected) and SpC (IM injected) were processed for immunofluorescent staining as previously described 9 , 17 . Briefly, the tissues were first deparaffinized followed by 30 minutes of antigen retrieval. 3% hydrogen peroxide was used to quench endogenous peroxidases followed by blocking using 100% background sniper solution for 13 minutes. Sections were then incubated in primary antibodies with 5% sniper diluted in TRIS overnight at 4 o C (pS129αS, Wako, 015-25191, 1:500; Iba1, Wako, 019-19741, 1:100; GFAP, Dako Cytomation, Z0334, 1:200) followed by incubation in secondary fluorophore conjugated antibody (Donkey anti-mouse 488, Donkey anti-rabbit 594). Sections were imaged using a Leica Stellaris 8 confocal microscope. Western blot (immunoblot) analysis. Lysate preparation and immunoblot analysis were performed as previously described 9 , 11 . Briefly, brain tissue from mice were dissected and stored at -80°C and frozen tissues were homogenized in TNE buffer [Tris-HCl 50 mM, NaCl 150 mM and EDTA 5 mM, and protease and phosphatase inhibitors (HALT; Thermo-Fisher; Waltham, MA)]. To obtain total lysate, homogenates were solubilized with 0.5% NP40, 0.5% DOC, and 1% SDS. For TX-100 non-ionic detergent fractionation, TNE homogenates were added to 1% TX-100 and sonicated prior to centrifugation at 100,000xg for 20 min. Supernatant was collected as the soluble fraction while the pellet was washed and centrifuged again in 1% TX-100. The resulting pellet was then reconstituted in TNE with detergents as the TX-100 insoluble fraction 9 , 25 . The protein content of the lysates were determined using the BCA assay (Pierce, Thermo; Rockford, IL) and samples were prepared to equal protein concentrations in reducing, SDS-sample, Laemmli buffer (Boston BioProducts; Ashland, MA). For Western blot analysis, protein lysates were run on Criterion™ TGX™ gels (BioRad, Hercules, CA) and transferred onto nitrocellulose membranes. Proteins on membranes were detected using appropriate primary antibodies followed by horseradish peroxidase ( HRP)-conjugated secondary antibodies (Invitrogen, Carlsbad, CA). Membranes were then developed using chemiluminescent substrates (BioRad and Thermo) and imaged using the ImageQuant LAS 4000 detection system (GE Life Sciences, Piscataway, NJ). Densitometry on Western blot images was analyzed using the ImageQuant TL 8.1 software (GE Life Sciences). Antibodies Primary antibodies used for immunohistochemistry and immunoblots are listed in Supplemental Table S1 . Statistical analysis All analyses were done using GraphPad Prism. Values are expressed as mean ± SD/SEM as indicated. Differences between means were analyzed by Student’s t -test, one-way ANOVA, or two-way ANOVA. ANOVA analyses were combined with the Tukey post-hoc test for multiple comparisons (Prism; Graph Pad Software). Log-rank (Mantel-Cox) test was used to assess significant differences in survival curves. An α value of 0.05 and adjusted P values for multiple comparisons were used to determine significance. Declarations Author Contributions: J.B. and M.K.L. conceived and designed the study. All authors were responsible for the acquisition of the data. J.B. S.C.V. and M.K.L. were responsible for data analysis and writing/editing of the manuscript. Competing Interest: Authors declare no competing financial or non-financial interests. Acknowledgements: This work was funded by Grants R01 NS086074, R01 NS092093, and ASAP-024407. ASAP-02447 is administered by Michael J. Fox Foundation (MJFF) on the behalf of the Aligning Science Across Parkinson's (ASAP) initiative. We thank Cindy Croy for help in generating the transgenic mouse cohorts and Dr. Poul Henning Jensen, Aarhus University for sharing the FILA-1 antibody. Data Availability: The datasets and images used and/or analyzed for the current study are available from the corresponding author on reasonable request. References Vila, M. & Przedborski, S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 10 Suppl, S58–62 (2004). Obeso, J.A. et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 16, 653 – 61 (2010). Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197–211 (2003). Li, J.Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14, 501–3 (2008). Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14, 504–6 (2008). Luk, K.C. et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209, 975–86 (2012). Chung, H.K., Ho, H.A., Perez-Acuna, D. & Lee, S.J. Modeling alpha-Synuclein Propagation with Preformed Fibril Injections. J Mov Disord 12, 139–151 (2019). Lee, M.K. et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99, 8968–73 (2002). Vermilyea, S.C. et al. Loss of tau expression attenuates neurodegeneration associated with alpha-synucleinopathy. Transl Neurodegener 11, 34 (2022). Braak, H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249 Suppl 3, III/1–5 (2002). Karim, M.R. et al. alpha-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener 15, 27 (2020). Teravskis, P.J. et al. A53T mutant alpha-synuclein induces tau dependent postsynaptic impairment independent of neurodegenerative changes. J Neurosci (2018). Colla, E. et al. Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha-Synucleinopathy In Vivo. J Neurosci 32, 3306–20 (2012). George, S. et al. Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease. Mol Neurodegener 14, 34 (2019). Sorrentino, Z.A. et al. Intrastriatal injection of alpha-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol Neurodegener 12, 40 (2017). Sorrentino, Z.A., Giasson, B.I. & Chakrabarty, P. alpha-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol 138, 1–21 (2019). Nanclares, C. et al. Dysregulation of astrocytic Ca(2+) signaling and gliotransmitter release in mouse models of alpha-synucleinopathies. Acta Neuropathol 145, 597–610 (2023). Sorrentino, Z.A. et al. Motor neuron loss and neuroinflammation in a model of alpha-synuclein-induced neurodegeneration. Neurobiol Dis 120, 98–106 (2018). Lindersson, E. et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279, 12924–34 (2004). Colla, E. et al. Accumulation of Toxic alpha-Synuclein Oligomer within Endoplasmic Reticulum Occurs in alpha-Synucleinopathy In Vivo. J Neurosci 32, 3301–5 (2012). Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18 (2007). Colla, E. et al. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. Neurobiology of Disease 111, 36–47 (2018). Killinger, B.A. & Kordower, J.H. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem 150, 605–611 (2019). Thi Lai, T. et al. Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson's disease mouse model. NPJ Parkinsons Dis 10, 32 (2024). Li, W. et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102, 2162–7 (2005). Sonustun, B. et al. Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy. Cells 11(2022). Zhang, S. et al. Post-translational modifications of soluble alpha-synuclein regulate the amplification of pathological alpha-synuclein. Nat Neurosci 26, 213–225 (2023). Lloyd, G.M. et al. Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human alpha-synuclein transgenic mice. Acta Neuropathol 143, 663–685 (2022). Additional Declarations (Not answered) Supplementary Files BarnesetalSupplTabFigsnpjpd.pdf Supplemental Figure Legends Figure S1. a) Injection of ESL or aS PFF into BrSt leads to shorter lifespan than IC/IS injections of ESL in TgA53T mice. *p<0.05 , **p<0.01 , One-way ANOVA, n=5-6 . b) aS pathology following BrSt or IC/IS injections are most prominent in BrSt and SpC at ES. Note that IC/IS injections also lead to more pS129 aS+ neurons in cortex but both models lack pS129 aS in hippocampus (Hippo). Abbreviations: end-stage lysate, ESL; alpha synuclein, aS; preformed fibril, PFF; brainstem, BrSt; intracortical/intrastriatal, IC/IS; spinal cord, SpC; end-stage, ES. Scale Bars: 100 mm. Figure S2. aS pathology following IC/IS injections of ESL into mice from TgA53T(H5) line. a) ES TgA53T(H5) mice (156 dpi) following IC/IS injection of ESL (S3000) were analyzed for accumulation of pS129 aS. While the TgA53T(H5) mice show more pS129 aS pathology in the cortex (CTX) and hippocampus (Hippo) than the IC/IS injected TgA53T(G2-3) mice (see Fig. S1B), most prominent pS129 aS pathology is localized to BrSt and SpC. b) Intermediate stage TgA53T (H5) (90 dpi) mice were analyzed for accumulation of pS129 aS. These mice did not show any overt motor abnormalities. There is a low level of pS129 aS staining in CTX with more abundant pS129 aS staining in the BrSt and SpC. Abbreviations: intracortical/intrastriatal, IC/IS; end-stage lysate, ESL; end-stage, ES; alpha synuclein, aS. Scale Bars: 100 mm. Figure S3.Quantitative analysis of increased microglia and astrocytes in ES TgA53T mice following ESL injection. a) Immunoblot analysis of whole-tissue lysates from CTX, BrSt, and SpC of saline-, ASL-, and ESL-injected mice for Iba-1 and corresponding quantitative analysis. Quantification of the blots confirms no change in the Iba1 signal in CTX but significant increases in BrSt and SpC (bottom). Values are mean±SD ( n =3 each). Two-way ANOVA, **p<0.01, ***p<0.001, ****p<0.0001, Tukey post hoc test for multiple comparisons. n=3. b) Immunoblot analysis of lysates in a for GFAP confirms no change in GFAP levels in CTX but significant increases in BrSt and SpC (bottom). Values are mean±SD ( n =3 each). One-way ANOVA, p <0.05. Tukey post hoc test for multiple comparisons. Abbreviations: end-stage, ES; end-stage lysate, ESL; cortex, CTX; brainstem, BrSt; spinal cord, SpC; asymptomatic lysate, ASL. Figure S4.Time courses of immunostained tissues from ESL BrSt-injected animals for Iba1 (a) and GFAP (b) show no increase in neuroinflammation within 45 dpi. Increased astrogliosis and microgliosis occur only at end-stage disease when severe αS pathology is present. Abbreviations: end-stage lysate, ESL; brainstem, BrSt; days post inoculation, dpi; alpha synuclein, aS. Scale bars: 25 µm. Figure S5. Neuroinflammation occurs after αS pathology in TgA53T mice IM injected with aS PFF. SpC sections from Control mice (a , ntg) and TgA53T mice injected with ESL into BrSt were analyzed at 30 dpi (b) 45 dpi (c) , and ES ( d , injected; e , aged). The sections were stained for pS129 aS and Iba1 or GFAP. Aggregated aS (pS129 aS) is seen as early as 15 dpi (b, arrow) but the overall morphology and density of Iba-1 and GFAP staining at 15- and 30-dpi (b,c) is comparable to nTg mice (a) . There are clear increases in Iba1 and GFAP staining with more established pS129 aS pathology in 45-dpi and ES animals (d, e) . Abbreviations: alpha synuclein, aS; intramuscular, IM; preformed fibril, PFF; spinal cord, SpC; end-stage lysate, ESL; brainstem, BrSt; days post inoculation, dpi; non transgenic, nTg; end-stage, ES. Scale Bar: 50 mm Figure S6. Immunoblot analysis of aS in S150 and P150 injected TgA53T mice. Whole tissue lysates (T) from CTX, BrSt, and SpC were further fractionated into 1% Tx-100 soluble (S) and insoluble (I) fractions. Equal amounts of proteins were analyzed for Total aS (a) and pS129 aS (b) . Virtually all of the pS129 aS accumulates in the insoluble fractions of BrSt and SpC, along with HMW aS ( ). While the highest levels of total aS is expressed in the CTX, the level of pS129 aS is minimal. Abbreviations: alpha synuclein, aS; cortex, CTX; brainstem, BrSt; spinal cord, SpC; high molecular weight, HMW. Figure S7. Analysis of aS oligomers in S150 and P150 fractions. a) Dot blot analysis of S150 and P150 for FILA1 and OC immunoreactivity. Equal amount of total protein (2 mg) from each fraction were dotted on to nitrocellulose membrane and probed with FILA1 antibody and OC antibody. b) Quantitative analysis of dot blots shown in a . Levels of immunoreactivity was normalized to AS-P150. In P150, both FILA1 and OC immunoreactivity are higher than in AS-P150. In S150, FILA1 levels are higher but the OC levels are not different than in AS-150. *p<0.05, **p<0.01, ****p<0.0001 , One-way ANOVA. n=3. c) S150 and P150 containing equal amount of protein (5 mg) were incubated with 50 mg/ml proteinase K (PK) and 1% Triton x-100 for 20 min on ice. The reaction was stopped by addition of 2mM (final concentration) of phenylmethylsulfonyl fluoride. The fractions were immunoblotted for total aS. Virtually all the aS in S150 is degraded by PK while both full length and partially proteolyzed aS survives PK treatment in P150. Abbreviations: alpha-synuclein, aS; asymptomatic, AS; end-stage, ES. Figure S8. Increased ER chaperones in ES mice injected with ESL into BrSt. a) Whole SpC lysates from nTg and End-Stage TgA53T mice injected with ESL were immunoblotted using anti-KDEL antibody (2D6, Invitrogen) that recognizes both Grp78 and Grp94. b) Quantitative analysis of a shows that both ER chaperones are increased in TgA53T mice. ** p<0.01 , **** p<0.0001 , unpaired t-test. nTg, n=3; Tg-End Stage, n=5. Abbreviations: endoplasmic reticulum, ER; end-stage, ES; end-stage lysate, ESL; non transgenic, nTg; transgenic, Tg. Cite Share Download PDF Status: Published Journal Publication published 27 Jun, 2025 Read the published version in International Journal of Molecular Sciences → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3982325","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":275844134,"identity":"ae418d4e-b901-4290-8222-748e76c07ef8","order_by":0,"name":"Michael Lee","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAnklEQVRIiWNgGAWjYDACHuYGBoYKCFuCSC2MQC1nSNbC2EaKFt2eg40PPs47HG3OwHzwNg8xWszONjYbztx2OHdnA1uyNXFazjO2SfMCtWw4wGMmTayW9t9/54C08H8jUsvZxjZmxgawLWxEajlzsFmy51h67obDbMaWc4jTknzww48a69wNx5sf3nhDjBYEYCZN+SgYBaNgFIwCfAAARQg1aEkvrmgAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-5865-9682","institution":"University of Minnesota","correspondingAuthor":true,"prefix":"","firstName":"Michael","middleName":"","lastName":"Lee","suffix":""},{"id":275844135,"identity":"adafa4a9-5aa5-4911-bdf8-fe62878e2acb","order_by":1,"name":"Justin Barnes","email":"","orcid":"","institution":"University of Minnesota","correspondingAuthor":false,"prefix":"","firstName":"Justin","middleName":"","lastName":"Barnes","suffix":""},{"id":275844136,"identity":"0a7799f7-2a50-4b44-af59-4fed0859a77c","order_by":2,"name":"Scott Vermilyea","email":"","orcid":"","institution":"University of Minnesota","correspondingAuthor":false,"prefix":"","firstName":"Scott","middleName":"","lastName":"Vermilyea","suffix":""},{"id":275844137,"identity":"d1016186-ca05-480c-b616-a85d9ee83b5b","order_by":3,"name":"Joyce Meints","email":"","orcid":"","institution":"University of Minnesota","correspondingAuthor":false,"prefix":"","firstName":"Joyce","middleName":"","lastName":"Meints","suffix":""},{"id":275844138,"identity":"23dfbfd0-7cec-41fd-affb-cf2a215d638a","order_by":4,"name":"Hector Martinez","email":"","orcid":"","institution":"University of Minnesota","correspondingAuthor":false,"prefix":"","firstName":"Hector","middleName":"","lastName":"Martinez","suffix":""}],"badges":[],"createdAt":"2024-02-23 15:25:57","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3982325/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3982325/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.3390/ijms26136254","type":"published","date":"2025-06-28T00:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":52033182,"identity":"3b2af219-0e2a-481e-bb22-ea71c3da390f","added_by":"auto","created_at":"2024-03-05 16:40:27","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":207536,"visible":true,"origin":"","legend":"\u003cp\u003eInjection of\u003cstrong\u003e \u003c/strong\u003e\u003cem\u003eTgA53T \u003c/em\u003ebrain-derived lysate into cortex/striatum or brain stem induces α-synucleinopathy and premature death in young \u003cem\u003eTgA53T\u003c/em\u003e mice. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003e\u003cem\u003e \u003c/em\u003eSchematic representation of the protocol used to generate the injected ESL and asymptomatic ASL. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e\u003cem\u003e \u003c/em\u003eAnalysis of ASL and ESL for total αS (top) and pS129 αS levels. While similar levels of total aS is present in ASL and ESL, ESL contains more pS129 aS than ASL. \u003cem\u003e\u003cstrong\u003ec)\u003c/strong\u003e\u003c/em\u003e\u003cem\u003e \u003c/em\u003eDiagrams depicting the stereotaxic injection sites for the IC/IS and BrSt injection models. Stereotaxic coordinates: IC/IS 2.0 mm lateral from the midline, +0.2 mm relative to bregma, and 0.8 and 2.6 mm deep from the dura; BrSt: 0.2 mm lateral from the midline, -7.34 mm from bregma, 3.75 mm deep from the dura. \u003cem\u003e\u003cstrong\u003ed)\u003c/strong\u003e\u003c/em\u003e\u003cem\u003e \u003c/em\u003eKaplan-Meier survival curve of mice IC/IS-injected with ESL and BrSt-injected animals with aS PFF, ESL, ASL, and saline. Control animals receiving saline and ASL all survived disease-free to 200 days post injection (dpi), excepting one animal injected with ASL that developed disease and died 136 dpi. **\u003cem\u003ep\u003c/em\u003e\u0026lt;0.01, IC/IS ESL vs BrSt ESL or BrSt PFF, Mantel-cox log-rank test. \u0026nbsp;All n=6 except BrSt (PFF), n=5. Abbreviations: alpha synuclein, aS; asymptomatic lysate, ASL; end-stage lysate, ESL; intracortical/intrastriatal, IC/IS; brainstem, BrSt; preformed fibril, PFF.\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj1.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/1f41e2bce44d526bc64f8a48.png"},{"id":52034274,"identity":"3c61670e-9875-43ba-b4c6-9186c2b031c4","added_by":"auto","created_at":"2024-03-05 16:48:27","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1429108,"visible":true,"origin":"","legend":"\u003cp\u003eAggregation of αS is induced by ESL in \u003cem\u003eTgA53T\u003c/em\u003emice with pathological distribution that is independent of injections site. \u0026nbsp;\u003cem\u003e\u003cstrong\u003ea) \u003c/strong\u003e\u003c/em\u003eAccumulation of pathological HMW aS species (*) and pS129 αS in affected brain regions in detergent insoluble faction. Total lysates (T) from unaffected CTX and affected BrSt and SpC from saline, ASL, and ESL of BrSt-injected animals were separated into TX-soluble (S) and TX-insoluble (I) fractions. Detection of total αS (left) demonstrates the presence of HMW insoluble αS species in SpC (*) ESL-inoculated mice. Immunoblots for pS129 αS clearly show a complete lack of pathological αS in ASL-injected animals and CTX of ESL-inoculated mice. Virtually all of HMW aS species (*) and pS129 aS partitions with the TX-insoluble fraction in BrSt and SpC. \u003cem\u003e\u003cstrong\u003eb) \u003c/strong\u003e\u003c/em\u003eAggregated aS, marked by pS129 aS immunoreactivity, is abundant in animals injected with ESL or aS PFF. \u003cem\u003e\u003cstrong\u003ec) \u003c/strong\u003e\u003c/em\u003eImmunoreactivity for pS129 αS occurs between 15- and 30-days post BrSt injection of ESL.\u003cem\u003e \u003c/em\u003e\u003cem\u003e\u003cstrong\u003eD) \u003c/strong\u003e\u003c/em\u003eDiagrams depicting the distribution of αS pathology as observed by immunohistochemical analysis. Shades of red denote the relative abundance of αS inclusions (% Area covered by pS129 aS). Note that the sections are unilateral to the injection site even though pathology is detected bilaterally. Abbreviations: alpha-synuclein, aS; end-stage lysate, ESL; high molecular weight, HMW; cortex, CTX; brainstem, BrSt; spinal cord, SpC; asymptomatic lysate, ASL; triton-X, TX; preformed fibril, PFF. Scale bars: 50 µm.\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj2.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/2db3644a11069cf68086bc3a.png"},{"id":52034275,"identity":"8f46a67c-4438-4e05-bdc7-968dba253053","added_by":"auto","created_at":"2024-03-05 16:48:27","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":859841,"visible":true,"origin":"","legend":"\u003cp\u003eNeuroinflammation is increased in affected brain regions. \u003cem\u003e\u003cstrong\u003ea,b) \u003c/strong\u003e\u003c/em\u003eTissue sections stained for Iba1 \u003cem\u003e\u003cstrong\u003e(a)\u003c/strong\u003e\u003c/em\u003eand GFAP \u003cem\u003e\u003cstrong\u003e(b)\u003c/strong\u003e\u003c/em\u003e. \u0026nbsp;BrSt and SpC from ESL-injected \u003cem\u003eTgA53T\u003c/em\u003e mouse reveal abundant activated microglia and astrocytes. Areas lacking αS pathology, such as the CTX, as well as animals injected with ASL, are free of glial activation. \u003cem\u003e\u003cstrong\u003ec,d) \u003c/strong\u003e\u003c/em\u003eBiochemical analysis of whole-tissue lysates from CTX, BrSt, and SpC of saline-, ASL-, and ESL-injected mice show robust increases in Iba1 \u003cem\u003e\u003cstrong\u003e(c)\u003c/strong\u003e\u003c/em\u003e and GFAP \u003cem\u003e\u003cstrong\u003e(d)\u003c/strong\u003e\u003c/em\u003ein BrSt and SpC or ESL injected mice. Quantitation of the blots are shown in Fig. S3. Abbreviations: alpha synuclein, aS; brainstem, BrSt; spinal cord, SpC; end-stage lysate, ESL; cortex, CTX; asymptomatic lysate, ASL. Scale bars: 25 µm.\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj3.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/0ec6f017da1d2095f0785f46.png"},{"id":52033184,"identity":"5b0db4b0-4a37-45d1-8020-76d1702f99e5","added_by":"auto","created_at":"2024-03-05 16:40:28","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":2064807,"visible":true,"origin":"","legend":"\u003cp\u003eNeuroinflammation occurs after αS pathology in \u003cem\u003eTgA53T \u003c/em\u003emice. BrSt sections from Control mice \u003cem\u003e\u003cstrong\u003e(a\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, ntg)\u003c/strong\u003e and \u003cem\u003eTgA53T\u003c/em\u003e mice injected with ESL into BrSt were analyzed at 30 dpi \u003cem\u003e\u003cstrong\u003e(b)\u003c/strong\u003e\u003c/em\u003e 45 dpi \u003cem\u003e\u003cstrong\u003e(c)\u003c/strong\u003e\u003c/em\u003e, and ES \u003cstrong\u003e(\u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ed\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, injected; \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ee\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, aged)\u003c/strong\u003e. The sections were stained for pS129 aS and Iba1 or GFAP. Aggregated aS (pS129 aS) is clearly seen in 30- and 45-dpi samples \u003cem\u003e\u003cstrong\u003e(b, c)\u003c/strong\u003e\u003c/em\u003e but the overall morphology and density of Iba-1 and GFAP staining is comparable to nTg mice \u003cem\u003e\u003cstrong\u003e(a)\u003c/strong\u003e\u003c/em\u003e, indicating that the presence of pS129 aS is not accompanied by obvious glial activation. In contrast, there is a clear increase in Iba1 and GFAP staining with well-established pS129 aS pathology in ES animals \u003cem\u003e\u003cstrong\u003e(d, e)\u003c/strong\u003e\u003c/em\u003e. Abbreviations: alpha synuclein, aS; brainstem, BrSt; end-stage lysate, ESL; end-stage, ES; non transgenic, nTg. Scare bar: 50 mm\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj4.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/f3670b0c475824897a97d78c.png"},{"id":52033179,"identity":"08313578-0604-4ed1-a19e-344da0361891","added_by":"auto","created_at":"2024-03-05 16:40:27","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1027648,"visible":true,"origin":"","legend":"\u003cp\u003eBoth soluble and insoluble fractions from ESL induces a-synucleinopathy in TgA53T mice. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003e Flow diagram showing the separation of S3000 into soluble (S150) and insoluble (P150) fractions. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e Biochemical analysis of S150 and P150 fractions derived from ASL and ESL. Equal amount of total protein was analyzed. P150 fractions from ASL contain very little aS while total aS and pS129 \u0026nbsp;aS are abundant in P150 fractions from ESL. Despite the abundant total aS in S150, much lower pS129 aS is present in the S150. \u003cem\u003e\u003cstrong\u003ec)\u003c/strong\u003e\u003c/em\u003e Kaplan-Meier survival curve of mice injected with S150 and P150 into BrSt. Also shown are the curve for the S3000-ESL injected mice shown in Fig. 1d. Both S150 and P150 injections lead to motor dysfunction and reduced life span. S3000, n=6; P150, n=7; S150, n=7; Sal, n=6. \u003cem\u003e\u003cstrong\u003ed)\u003c/strong\u003e\u003c/em\u003eNeuropathological analysis of affected S150 and P150 injected animals show expected distribution of aS pathology (pS129 aS) and corresponding neuroinflammation (Iba1 and GFAP). Abbreviations: end-stage lysate, ESL; asymptomatic lysate, ASL; alpha synuclein, aS. Scale bars: 50 µm for pS129 aS, 25 µm for Iba1 and GFAP.\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj5.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/b68c459bc9433d69b7538c39.png"},{"id":52033180,"identity":"3037c050-4842-456e-a0b7-db4fd4a9c890","added_by":"auto","created_at":"2024-03-05 16:40:27","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":970608,"visible":true,"origin":"","legend":"\u003cp\u003eER-enriched fraction from ES \u003cem\u003eTgA53T\u003c/em\u003e mice, containing ER-associated aS, is highly pathogenic. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003e Subcellular fractions from BrSt/SpC and CTX were analyzed for pS129 aS, total aS, and organelle markers (Cytochrome C, CytC-mitochondria; Calnexin, Calnx-ER; Transketolase, KT-Cytosol). Calnexin-enriched ER fraction (P100) is relatively free of CytC and TK. pS129 aS is enriched in P100 from BrSt/SpC. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e Kaplan-Meier survival curve of mice injected with P100(ER) fractions from BrSt/SpC (BS/SC) or CTX. For reference, curve for P150 injected animals from Fig. 4\u003cem\u003ec\u003c/em\u003e is also shown. \u003cem\u003e***p\u0026lt;0.001\u003c/em\u003e, ER(BrSt) vs P150(ES), Mantel-cox log-rank test. P150(ES), n=7; ER(BrSt/SpC), n=7; ER(CTX), n=6. \u0026nbsp;\u003cem\u003e\u003cstrong\u003ec)\u003c/strong\u003e\u003c/em\u003eNeuropathological analysis show that ER(BS/SC) fraction induces pS129 aS pathology in \u003cem\u003eTgA53T\u003c/em\u003e mice, particularly in BrSt and SpC. In contrast, ER(CTX) fraction do not cause pS129 pathology. Abbreviations: endoplasmic reticulum, ER; end-stage, ES; alpha synuclein, aS; brainstem, BrSt/BS; spinal cord, SpC/SC; cortex, CTX. Scale bar: 50 µm.\u003c/p\u003e","description":"","filename":"BarnesetalFiguresnpj6.png","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/508d68a24532a8ca6be87360.png"},{"id":85876543,"identity":"ee221b1a-8af1-4152-9300-864975889ae6","added_by":"auto","created_at":"2025-07-02 15:15:42","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":7373039,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/af5441be-1f9d-49ef-aa64-c3168c671aa0.pdf"},{"id":52033185,"identity":"0348861c-df1e-4706-98ce-16d24ae67e03","added_by":"auto","created_at":"2024-03-05 16:40:28","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":10385140,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplemental Figure Legends\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S1.\u003c/strong\u003e \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003eInjection of ESL or aS PFF into BrSt leads to shorter lifespan than IC/IS injections of ESL in TgA53T mice. \u003cem\u003e*p\u0026lt;0.05\u003c/em\u003e, \u003cem\u003e**p\u0026lt;0.01\u003c/em\u003e, One-way ANOVA, \u003cem\u003en=5-6\u003c/em\u003e. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e aS pathology following BrSt or IC/IS injections are most prominent in BrSt and SpC at ES. Note that IC/IS injections also lead to more pS129 aS+ neurons in cortex but both models lack pS129 aS in hippocampus (Hippo). Abbreviations: end-stage lysate, ESL; alpha synuclein, aS; preformed fibril, PFF; brainstem, BrSt; intracortical/intrastriatal, IC/IS; spinal cord, SpC; end-stage, ES. Scale Bars: 100 mm.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S2.\u003c/strong\u003e aS pathology following IC/IS injections of ESL into mice from \u003cem\u003eTgA53T(H5)\u003c/em\u003e line. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003eES \u003cem\u003eTgA53T(H5)\u003c/em\u003e mice (156 dpi) following IC/IS injection of ESL (S3000) were analyzed for accumulation of pS129 aS. While the \u003cem\u003eTgA53T(H5)\u003c/em\u003e mice show more pS129 aS pathology in the cortex (CTX) and hippocampus (Hippo) than the IC/IS injected \u003cem\u003eTgA53T(G2-3)\u003c/em\u003emice (see Fig. S1B), most prominent pS129 aS pathology is localized to BrSt and SpC. \u0026nbsp;\u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003eIntermediate stage \u003cem\u003eTgA53T\u003c/em\u003e(H5) (90 dpi) mice were analyzed for accumulation of pS129 aS. These mice did not show any overt motor abnormalities. \u0026nbsp;There is a low level of pS129 aS staining in CTX with more abundant pS129 aS staining in the BrSt and SpC. Abbreviations: intracortical/intrastriatal, IC/IS; end-stage lysate, ESL; end-stage, ES; alpha synuclein, aS. Scale Bars: 100 mm.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S3.\u003c/strong\u003eQuantitative analysis of increased microglia and astrocytes in ES \u003cem\u003eTgA53T\u003c/em\u003emice following ESL injection. \u003cem\u003e\u003cstrong\u003ea) \u003c/strong\u003e\u003c/em\u003eImmunoblot analysis of whole-tissue lysates from CTX, BrSt, and SpC of saline-, ASL-, and ESL-injected mice for Iba-1 and corresponding quantitative analysis. \u0026nbsp;Quantification of the blots confirms no change in the Iba1 signal in CTX but significant increases in BrSt and SpC (bottom). Values are mean±SD (\u003cem\u003en\u003c/em\u003e=3 each). Two-way ANOVA,\u003cem\u003e **p\u0026lt;0.01, ***p\u0026lt;0.001, ****p\u0026lt;0.0001, \u003c/em\u003eTukey \u003cem\u003epost hoc\u003c/em\u003e test for multiple comparisons. n=3. \u003cem\u003e\u003cstrong\u003eb) \u003c/strong\u003e\u003c/em\u003eImmunoblot analysis of lysates in \u003cem\u003e\u003cstrong\u003ea\u003c/strong\u003e\u003c/em\u003efor GFAP confirms no change in GFAP levels in CTX but significant increases in BrSt and SpC (bottom). Values are mean±SD (\u003cem\u003en\u003c/em\u003e=3 each). One-way ANOVA, *\u003cem\u003ep\u003c/em\u003e\u0026lt;0.05. Tukey \u003cem\u003epost hoc\u003c/em\u003e test for multiple comparisons. \u0026nbsp;Abbreviations: end-stage, ES; end-stage lysate, ESL; cortex, CTX; brainstem, BrSt; spinal cord, SpC; asymptomatic lysate, ASL.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S4.\u003c/strong\u003eTime courses of immunostained tissues from ESL BrSt-injected animals for Iba1 \u003cem\u003e\u003cstrong\u003e(a)\u003c/strong\u003e\u003c/em\u003eand GFAP \u003cem\u003e\u003cstrong\u003e(b)\u003c/strong\u003e\u003c/em\u003e show no increase in neuroinflammation within 45 dpi. Increased astrogliosis and microgliosis occur only at end-stage disease when severe αS pathology is present. Abbreviations: end-stage lysate, ESL; brainstem, BrSt; days post inoculation, dpi; alpha synuclein, aS. Scale bars: 25 µm.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S5. \u003c/strong\u003eNeuroinflammation occurs after αS pathology in \u003cem\u003eTgA53T \u003c/em\u003emice IM injected with aS PFF. SpC sections from Control mice \u003cem\u003e\u003cstrong\u003e(a\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, ntg)\u003c/strong\u003e and \u003cem\u003eTgA53T\u003c/em\u003e mice injected with ESL into BrSt were analyzed at 30 dpi \u003cem\u003e\u003cstrong\u003e(b)\u003c/strong\u003e\u003c/em\u003e 45 dpi \u003cem\u003e\u003cstrong\u003e(c)\u003c/strong\u003e\u003c/em\u003e, and ES \u003cstrong\u003e(\u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ed\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, injected; \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ee\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e, aged)\u003c/strong\u003e. The sections were stained for pS129 aS and Iba1 or GFAP. Aggregated aS (pS129 aS) is seen as early as 15 dpi \u003cem\u003e\u003cstrong\u003e(b, arrow)\u003c/strong\u003e\u003c/em\u003e but the overall morphology and density of Iba-1 and GFAP staining at 15- and 30-dpi \u003cem\u003e\u003cstrong\u003e(b,c)\u003c/strong\u003e\u003c/em\u003e is comparable to nTg mice \u003cem\u003e\u003cstrong\u003e(a)\u003c/strong\u003e\u003c/em\u003e. There are clear increases in Iba1 and GFAP staining with more established pS129 aS pathology in 45-dpi and ES animals \u003cem\u003e\u003cstrong\u003e(d, e)\u003c/strong\u003e\u003c/em\u003e. Abbreviations: alpha synuclein, aS; intramuscular, IM; preformed fibril, PFF; spinal cord, SpC; end-stage lysate, ESL; brainstem, BrSt; days post inoculation, dpi; non transgenic, nTg; end-stage, ES. Scale Bar: 50 mm\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S6\u003c/strong\u003e. Immunoblot analysis of aS in S150 and P150 injected \u003cem\u003eTgA53T\u003c/em\u003e mice. Whole tissue lysates (T) from CTX, BrSt, and SpC were further fractionated into 1% Tx-100 soluble (S) and insoluble (I) fractions. Equal amounts of proteins were analyzed for Total aS \u003cem\u003e\u003cstrong\u003e(a)\u003c/strong\u003e\u003c/em\u003e and pS129 aS \u003cem\u003e\u003cstrong\u003e(b)\u003c/strong\u003e\u003c/em\u003e. Virtually all of the pS129 aS accumulates in the insoluble fractions of BrSt and SpC, along with HMW aS (*). While the highest levels of total aS is expressed in the CTX, the level of pS129 aS is minimal. Abbreviations: alpha synuclein, aS; cortex, CTX; brainstem, BrSt; spinal cord, SpC; high molecular weight, HMW.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S7.\u003c/strong\u003e Analysis of aS oligomers in S150 and P150 fractions. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003e Dot blot analysis of S150 and P150 for FILA1 and OC immunoreactivity. Equal amount of total protein (2 mg) from each fraction were dotted on to nitrocellulose membrane and probed with FILA1 antibody and OC antibody. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e Quantitative analysis of dot blots shown in \u003cem\u003e\u003cstrong\u003ea\u003c/strong\u003e\u003c/em\u003e. Levels of immunoreactivity was normalized to AS-P150. In P150, both FILA1 and OC immunoreactivity are higher than in AS-P150. In S150, FILA1 levels are higher but the OC levels are not different than in AS-150. \u003cem\u003e*p\u0026lt;0.05, **p\u0026lt;0.01, ****p\u0026lt;0.0001\u003c/em\u003e, One-way ANOVA. n=3. \u003cem\u003e\u003cstrong\u003ec)\u003c/strong\u003e\u003c/em\u003e S150 and P150 containing equal amount of protein (5 mg) were incubated with 50 mg/ml proteinase K (PK) and 1% Triton x-100 for 20 min on ice. The reaction was stopped by addition of 2mM (final concentration) of phenylmethylsulfonyl fluoride. The fractions were immunoblotted for total aS. Virtually all the aS in S150 is degraded by PK while both full length and partially proteolyzed aS survives PK treatment in P150. Abbreviations: alpha-synuclein, aS; asymptomatic, AS; end-stage, ES.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure S8.\u003c/strong\u003e Increased ER chaperones in ES mice injected with ESL into BrSt. \u003cem\u003e\u003cstrong\u003ea)\u003c/strong\u003e\u003c/em\u003eWhole SpC lysates from nTg and End-Stage \u003cem\u003eTgA53T\u003c/em\u003e mice injected with ESL were immunoblotted using anti-KDEL antibody (2D6, Invitrogen) that recognizes both Grp78 and Grp94. \u003cem\u003e\u003cstrong\u003eb)\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e \u003c/strong\u003eQuantitative analysis of \u003cem\u003e\u003cstrong\u003ea \u003c/strong\u003e\u003c/em\u003eshows that both ER chaperones are increased in TgA53T mice. **\u003cem\u003ep\u0026lt;0.01\u003c/em\u003e, ****\u003cem\u003ep\u0026lt;0.0001\u003c/em\u003e, unpaired t-test. nTg, n=3; Tg-End Stage, n=5. Abbreviations: endoplasmic reticulum, ER; end-stage, ES; end-stage lysate, ESL; non transgenic, nTg; transgenic, Tg.\u003c/p\u003e","description":"","filename":"BarnesetalSupplTabFigsnpjpd.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3982325/v1/04f09897f4728e710a1d77e4.pdf"}],"financialInterests":"(Not answered)","formattedTitle":"Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site","fulltext":[{"header":"Introduction","content":"\u003cp\u003eParkinson\u0026rsquo;s disease (PD) is a common late-onset, progressive neurodegenerative disorder characterized by progressive degeneration of multiple neuronal populations, particularly the dopaminergic (DAergic) neurons of the substantia nigra pars compacta (SNpc), and the presence of intracellular aggregates of α-synuclein (αS) termed Lewy bodies (LBs) and neurites (LNs). While the etiology of PD is unknown in most cases, degenerating neuronal populations in PD exhibit α-synuclein (αS) abnormalities and mutations in the \u003cem\u003eαS\u003c/em\u003e gene cause familial PD, indicating that the αS abnormalities are mechanistically linked to pathogenesis of PD and other α-synucleinopathies\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe temporal analysis of αS pathology in human cases\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e indicates that αS pathology in the PD brain originates in several focal sites, particularly the dorsal motor nucleus of vagus (DMV) and the anterior olfactory nucleus. With the preclinical progression of the disease, αS pathology moves anteriorly in a topographically defined manner until reaching the cortex during the symptomatic stage. This staging led to the hypothesis that αS pathology moves via cell-to-cell transmission of amyloidogenic αS species that serves as a conformational template to seed pathology. This hypothesis was also further supported by the presence of LBs in fetal dopamine neurons grafted into PD patients \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. Cell-to-cell transmission of α-synucleinopathy has received formal experimental support from brain injection studies establishing αS spreads transynaptically in mice\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Currently, direct inoculation of αS pre-formed fibrils (PFFs) or tissue lysates/fractions containing αS aggregates can induce αS pathology when directly injected into the central nervous system (CNS) or peripherally\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. However, most current studies involve the use of αS PFF derived from recombinant αS. Thus, it is unknown if the spatial-temporal pattern of αS pathology are comparable following inoculation of various pathogenic αS species to various brain regions of αS Tg models.\u003c/p\u003e \u003cp\u003eTo better understand the spreading of α-synucleinopathy, we directly compared spatial-temporal pattern of αS pathology following inoculation of pathogenic αS species into different brain regions (cortex/striatum and dorsal brain stem) and skeletal muscle of A53T mutant human αS (\u003cem\u003eTgA53T\u003c/em\u003e) transgenic mice\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. We show that all three inoculation sites lead to end-stage pathology that is indistinguishable to that observed with aging \u003cem\u003eTgA53T\u003c/em\u003e mice, indicating that specific neuronal populations are predisposed to the effects of toxic αS species \u003cem\u003ein vivo.\u003c/em\u003e Temporal analysis show that overt neuroinflammation occurs after onset of αS pathology, supporting the view that inflammation is not the primary driver for the initial onset and spreading of αS pathology. We also show that both the soluble and insoluble fractions from end-stage \u003cem\u003eTgA53T\u003c/em\u003e mice can initiate pathology in younger \u003cem\u003eTgA53T\u003c/em\u003e mice. Further, endoplasmic reticulum (ER) associated αS from the end-stage \u003cem\u003eTgA53T\u003c/em\u003e mice induces pathology sooner than other lysates or αS PFF. Thus, multiple species of αS are capable of inducing pathology \u003cem\u003ein vivo\u003c/em\u003e and suggest the need to separate such entities to further clarify the form of αS that is necessary to seed pathological alterations \u003cem\u003ein vivo.\u003c/em\u003e\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eLysates from symptomatic\u003c/b\u003e \u003cb\u003eTgA53T\u003c/b\u003e \u003cb\u003emice and αS PFF induce α-synucleinopathy with similar end-stage distribution.\u003c/b\u003e\u003c/p\u003e \u003cp\u003eAlthough the intracortical/intrastriatal (IC/IS) transmission model shows the induction and spread of αS pathology in \u003cem\u003eTgA53T\u003c/em\u003e mice\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e, studies show that injections of pathogenic αS lysates or preformed αS fibrils (PFF) in multiple areas, including the skeletal muscle, can induce widespread αS pathology over time\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Thus, we examined whether the inoculation site impacts the onset and spread of αS pathology in \u003cem\u003eTgA53T\u003c/em\u003e mice. Because brain stem (BrSt) neurons are affected early by αS pathology in both human PD\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e and in the \u003cem\u003eTgA53T\u003c/em\u003e mouse model\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e, we compared the disease produced by the IC/IS inoculation with the BrSt injections of αS PFF. We injected young, disease-free 3\u0026ndash;6 month-old \u003cem\u003eTgA53T\u003c/em\u003e mice (all from line G2-3 unless noted) with end-stage lysate (ESL or S3000, a crude 3000xg pooled lysate) from BrSt/Spinal Cord (SpC) of end-stage (ES) affected \u003cem\u003eTgA53T\u003c/em\u003e mice or lysates from disease-free (asymptomatic lysate, ASL) 5\u0026ndash;6 months old \u003cem\u003eTgA53T\u003c/em\u003e mice (Fig.\u0026nbsp;1a-c). Immunoblot analysis (Fig.\u0026nbsp;1b) show that both ASL and ESL contain similar amount of total αS but ESL contains greater amount of pS129αS, consistent with pathology in ES \u003cem\u003eTgA53T\u003c/em\u003e mice. Like that seen by Luk \u003cem\u003eet al\u003c/em\u003e. (2012), the mean of survival for bilateral IC/IS injected mice was 98\u0026thinsp;\u0026plusmn;\u0026thinsp;8.6 days post-inoculation (dpi) (Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) (Fig.\u0026nbsp;1d, Supplemental Fig.\u0026nbsp;1). Unilateral inoculation of ESL into the BrSt resulted in earlier onset of motor dysfunction with the mean survival of 71.3\u0026thinsp;\u0026plusmn;\u0026thinsp;18.7 dpi (Fig.\u0026nbsp;1d, S1\u003cem\u003ea\u003c/em\u003e), a significantly shorter disease time course than with IC/IS dual injections. Inoculation of αS PFF into BrSt leads to mean survival time (77.4\u0026thinsp;\u0026plusmn;\u0026thinsp;13.16 dpi, n\u0026thinsp;=\u0026thinsp;5) that is like the ESL inoculation (Fig.\u0026nbsp;1d, S1\u003cem\u003ea\u003c/em\u003e). All the mice injected with ASL or saline remained disease free at ~\u0026thinsp;150 dpi (Fig.\u0026nbsp;1d) except one ASL-inoculated animal who succumbed to disease prematurely died at ~\u0026thinsp;9 months of age, a time point where normal aged \u003cem\u003eTgA53T\u003c/em\u003e mice start to show disease\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Thus, it is likely that this animal developed disease independently of the injected lysate.\u003c/p\u003e \u003cp\u003eBiochemical analysis of the ESL inoculated animals confirms that the ESL, but not ASL, leads to αS pathology (Fig.\u0026nbsp;2a). Analysis of Triton X100-detergent soluble and insoluble fractions reveal the accumulation of insoluble high molecular weight (HMW) species of αS (Fig.\u0026nbsp;2a, asterisks) in the SpC of ESL injected mice. In the ESL injected mice, insoluble pS129αS accumulates in BrSt and SpC, corresponding to the regions most affected by αS pathology (Fig.\u0026nbsp;2a). Consistent with lack of αS pathology, pS129αS does not accumulate in ASL (Fig.\u0026nbsp;2a) or Saline (not shown) injected mice. This pattern of αS pathology is equivalent to that seen with the ES \u003cem\u003eTgA53T\u003c/em\u003e mice that normally develop α-synucleinopathy from aging\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eImmunohistochemical detection of pS129αS demonstrates robust staining in multiple brain tissues from IC/IS- and BrSt-injected end-stage animals (Fig.\u0026nbsp;2b). Consistent with the lack of motor phenotype, no pathological alterations are noted in ASL-inoculated mice (Fig.\u0026nbsp;2b) or saline-injected animals (data not shown). Significantly, despite the differences in the site of inoculation (IC/IS vs BrSt), the overall patterns of pathology in the ES mice were comparable to each other with most abundant pathology in the BrSt and SpC (Fig.\u0026nbsp;2b), a pattern very similar to what is seen in the \u003cem\u003eTgA53T\u003c/em\u003e mice that naturally develop αS pathology with aging\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. However, we noted that IC/IS injected animals exhibit more pS129αS pathology in CTX compared to BrSt injected animals (Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e\u003cem\u003eb\u003c/em\u003e). To determine if components of lysates other than pathogenic αS could be responsible for the distribution of the pathology, we also examined animals that were BrSt injected with αS PFF. Our results show that the pattern of pathology seen in the ESL inoculated animals is very similar to animals injected with αS PFF into BrSt (Fig.\u0026nbsp;2b, S1\u003cem\u003eb\u003c/em\u003e). Moreover, the pattern of αS pathology induced by BrSt injections are also very similar to the pathology achieved in this line of mice by peripheral, intramuscular (IM) inoculation of αS PFF\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. To determine if the prominent subcortical pathology is unique to \u003cem\u003eTgA53T(G2-3)\u003c/em\u003e line or occurs in another line of \u003cem\u003eTgA53T\u003c/em\u003e, we performed IC/IS injections on \u003cem\u003eTgA53T(H5)\u003c/em\u003e, which express 50% less αS than \u003cem\u003eTgA53T(G2-3)\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Because of lower transgene expression, injected \u003cem\u003eTgA53T(H5)\u003c/em\u003e animals developed progressive motor phenotype later (~\u0026thinsp;150 dpi) than the \u003cem\u003eTgA53T(G2-3)\u003c/em\u003e (~\u0026thinsp;100 dpi) following IC/IS injections of αS PFF. Neuropathological analysis shows that, as with \u003cem\u003eTgA53T(G2-3)\u003c/em\u003e, αS pathology at ES mice was most abundant in BrSt/SpC region (Fig. S2). Significantly, the \u003cem\u003eTgA53T(H5)\u003c/em\u003e animals also showed a more widespread distribution of αS pathology, including αS pathology in the hippocampus (Fig. S2\u003cem\u003ea\u003c/em\u003e). In summary, in all animals inoculated with ESL or αS PFF showed most severe BrSt and SpC αS pathology, regardless of initial sites of injections.\u003c/p\u003e \u003cp\u003eCollectively, these results indicate that in \u003cem\u003eTgA53T\u003c/em\u003e mice, the ES distribution of αS pathology is independent of inoculation site and likely determined by factors other than local seeding by pathogenic αS. Moreover, because our Tg models show highest levels of transgene expression in the CTX\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e, relative lack of forebrain pathology is not because of insufficient transgene expression in this area. While previous studies with the IC/IS injection model show that cortical and striatal αS pathology occurs prior to BrSt or SpC\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e, we observe more prominent early subcortical pathology with the BrSt inoculation. Thus, following the BrSt inoculation, the appearance of pS129αS over time shows that initial αS pathology develops proximal to the inoculation site where αS pathology is seen in the pons by 30 dpi (Fig.\u0026nbsp;2c). By 45 dpi, regions rostral and caudal to the BrSt inoculation sites exhibits αS pathology (Fig.\u0026nbsp;2c). Thus, we propose that following BrSt injection of pathogenic αS, the pathology spreads both rostral and caudal directions but most prominent pathology occurs in subcortical regions (Fig.\u0026nbsp;2d). Analysis of IC/IS injected \u003cem\u003eTgA53T(H5)\u003c/em\u003e animals at intermediate stage (90 dpi) shows the presence of pS129αS in the CTX but more obvious pS129αS pathology is seen in the BrSt and SpC areas (Fig. S2b). Overall, current results collectively show that regardless of the initial injection site, subcortical areas (e.g. BrSt, SpC) exhibit earliest αS pathology and culminates in most severe αS pathology at ES \u003cem\u003eTgA53T\u003c/em\u003e mice.\u003c/p\u003e \u003cp\u003e \u003cb\u003eNeuroinflammation follows onset of α-synucleinopathy.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eIt has been proposed that inoculation with pathogenic αS could lead to early neuroinflammation that may promote further propagation of α-synucleinopathy\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. Thus, we examined the spatial-temporal relationship between αS pathology and neuroinflammation. First, we confirmed that at ES, animals following BrSt injection exhibit coincident αS pathology and neuroinflammation. Tissue sections from BrSt-injected animals were stained for microglia (Iba1; Fig.\u0026nbsp;3a) and astrocytes (GFAP; Fig.\u0026nbsp;3b). Based on the morphology of the cells, no obvious neuroinflammatory changes are seen in absence of significant αS pathology, such as in CTX (Fig.\u0026nbsp;3a,\u003cem\u003eb\u003c/em\u003e) and in animals injected with saline (not show) or ASL (Fig.\u0026nbsp;3a,\u003cem\u003eb\u003c/em\u003e). However, in ES animals following ESL injection, areas with significant αS pathology (BrSt, SpC) exhibit abundant microglia and astrocytes with highly activated morphology. Immunoblotting for Iba1 and GFAP reveals no change in Ctx, but a significant increase in BrSt and SpC of ESL-injected mice at ES disease (Fig.\u0026nbsp;3c,\u003cem\u003ed\u003c/em\u003e; Fig. S3).\u003c/p\u003e \u003cp\u003eTo better determine the spatial-temporal relationship between the onset of microglial activation and αS pathology, the sections from BrSt inoculated mice harvested at 15-, 30-, and 45-dpi that were evaluated for αS pathology (Fig, 2\u003cem\u003ec\u003c/em\u003e) were stained for microglia (Iba-1) and astrocytes (GFAP) (Fig. S4). With BrSt inoculation, αS pathology is seen in the pons by 30 dpi (Fig.\u0026nbsp;2c). However, there is no obvious signs of astrocytic or microglial activation at 30- or 45-dpi (Fig. S4). Because αS pathology is still sparse at 45 dpi, we performed double immunofluorescence analysis of pS129αS with Iba1 or GFAP (Fig.\u0026nbsp;4) to determine if presence of αS pathology could be associated with local changes in inflammatory changes. Double immunofluorescence analyses show that that while αS pathology in ES mice are clearly associated with nearby reactive astrocytes and microglia, such glial responses do not accompany αS pathology at 30- or 45-dpi (Fig.\u0026nbsp;4b,\u003cem\u003ec\u003c/em\u003e). Similar analysis of early-stage mice following IM αS PFF injections show that initial onset of pS129αS pathology in SpC, occurring as early as 15\u0026ndash;30 dpi, is not accompanied by obvious glial activation (Fig. S5). While other A53T Tg models show αS pathology in astrocytes\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, we do not observe significant pS129αS in astrocytes at ES mice (Fig.\u0026nbsp;4)\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eCollectively, our results indicate that glial activation, particularly activation of microglia, is only evident after substantial αS pathology is established. Similar pattern of initial αS pathology followed by neuroinflammation was reported with IM inoculation of M83 line\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Thus, while microglia and astrocytes may modulate neuronal spreading of αS pathology or neuronal survival, our results indicate that it is unlikely that the neuroinflammation is a significant factor in the initial onset of αS pathology in \u003cem\u003eTgA53T\u003c/em\u003e model of α-synucleinopathy.\u003c/p\u003e\n\u003ch3\u003eBoth highly soluble and insoluble fractions induce αS pathology\u003c/h3\u003e\n\u003cp\u003eBecause αS fibrils and disease associated aggregates in \u003cem\u003eTgA53T\u003c/em\u003e mice are detergent insoluble\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e, we tested whether the induction of αS pathology by the ESL is mediated by the insoluble αS species. The pathogenic S3000 ESL was centrifuged at 150,000x\u003cem\u003eg\u003c/em\u003e to obtain highly soluble (supernatant, S150) and insoluble (pellet, P150) fractions (Fig.\u0026nbsp;5a). Biochemical analyses of the fractions show that very little αS is found in P150 from asymptomatic animals (Fig.\u0026nbsp;5b). Moreover, most of the pS129αS, representing the overt αS pathology, is highly enriched in the P150 fractions from the symptomatic mice (Fig.\u0026nbsp;5b). In contrast, the amount of total αS is the same in the S150 fractions, regardless of the disease state of the animal (Fig.\u0026nbsp;5b). Despite the high levels of total αS, the levels of pS129αS in S150 is lower than in the P150 with no differences between the disease state of the animal (Fig.\u0026nbsp;5b). Thus, we expected that αS pathology would be selectively induced by the P150-ESL fraction.\u003c/p\u003e \u003cp\u003eFollowing BrSt injections of P150 and S150 fractions, we were surprised to find that, regardless of the solubility of the inoculated material, inoculated \u003cem\u003eTgA53T\u003c/em\u003e mice developed motor dysfunction leading to premature death with average lifespans of 75\u0026thinsp;\u0026plusmn;\u0026thinsp;7 dpi for P150 fraction and 88\u0026thinsp;\u0026plusmn;\u0026thinsp;3 dpi for S150 fraction (Fig.\u0026nbsp;5c). While 2 out of 7 subjects injected with S150 did not develop disease phenotype by 150 dpi, for those animals that died prematurely, there was no differences in the average lifespan (Fig.\u0026nbsp;5c, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.1397) between S150 and P150 injected groups.\u003c/p\u003e \u003cp\u003eHistological (Fig.\u0026nbsp;5d) and biochemical (Fig. S6) analyses of ES P150- and S150-injected animals demonstrate virtually indistinguishable αS pathology both in the spatial pattern and severity of αS aggregation (compare Figs.\u0026nbsp;2 and 5, S6). Aggregation of αS occurred throughout the CNS but was most robust in the BrSt and SpC (Fig.\u0026nbsp;5d). Biochemical analysis of brain tissue also reveals accumulation detergent insoluble αS species in the insoluble fraction from BrSt and SpC (Fig. S6a) and dramatic increases in pS129αS in both BrSt and SpC (Fig. S6\u003cem\u003eb\u003c/em\u003e). Finally, based on immunostaining for Iba1 and GFAP, the distribution and intensity of neuroinflammation is similar in S150- and P150-BrSt-injected animals (Fig.\u0026nbsp;5d), and is nearly identical to that observed in ESL-injected mice (see Fig.\u0026nbsp;3). Thus, by three broad metrics: survival, IHC, and biochemistry, the α-synucleinopathy and disease induced by injection of all three end-stage lysates (S3000, S150, P150) are essentially identical.\u003c/p\u003e \u003cp\u003eSince S3000 ASL does not induce disease and there is no obvious differences between S150 from ASL and ESL on our immunoblot analysis, S150 from ESL may contain soluble pathogenic αS conformers that is SDS labile. Thus, incomplete penetrance of end-stage S150 to cause disease could be due to the possibility that toxic αS assemblies in S150 fractions are more prone to degradation following cellular uptake compared to more mature insoluble toxic αS species in P150 (Fig.\u0026nbsp;5b). As an initial test of this hypothesis, we performed dot blot analysis of P150 and S150 for αS oligomers, using FILA1\u003csup\u003e19,20\u003c/sup\u003e and OC antibody\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e (Fig. S7\u003cem\u003ea,b\u003c/em\u003e). We previously showed that FILA1 can recognize both soluble and insoluble αS aggregates derived of \u003cem\u003eTgA53T\u003c/em\u003e model\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e and OC antibody selectively recognizes mature fibrils\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Our results show that while levels of FILA1\u0026thinsp;+\u0026thinsp;oligomers are similar between P150 and S150, the levels of OC\u0026thinsp;+\u0026thinsp;oligomers are significantly more abundant in P150 (Fig. S7\u003cem\u003ea,b\u003c/em\u003e). We also subjected S150 and P150 to proteinase K treatment as more compact mature aggregates should be more resistant to proteinase K treatment. The results show that αS in P150 is more resistant to proteinase K proteolysis than αS in S150 (Fig. S7\u003cem\u003ec\u003c/em\u003e). Thus, we conclude that the presence of FILA1\u0026thinsp;+\u0026thinsp;oligomers/aggregates in both S150 and P150 are pathogenic. Further, more labile FILA1\u0026thinsp;+\u0026thinsp;oligomers in S150 may be responsible for the partial penetrance of S150 in inducing disease.\u003c/p\u003e \u003cp\u003e \u003cb\u003eMicrosomes from symptomatic\u003c/b\u003e \u003cb\u003eTgA53T\u003c/b\u003e \u003cb\u003emice induce rapid α-synucleinopathy.\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWe previously showed that α-synucleinopathy in \u003cem\u003eTgA53T\u003c/em\u003e mice is associated with accumulation of αS oligomers/aggregates in endoplasmic reticulum (ER) and chronic ER stress contributes to neurodegeneration\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. Analyses of \u003cem\u003eTgA53T\u003c/em\u003e mice inoculated with S3000 ESL show that αS pathology in these mice are also associated with signs of chronic ER stress (Fig. S8), suggesting that ER stress occurs even when α-synucleinopathy is induced by exogenous inoculation of pathogenic αS. We recently showed that ER enriched microsomes from \u003cem\u003eTgA53T\u003c/em\u003e mice, containing αS aggregates, are highly toxic to cultured neurons and aggressively induces αS aggregates and cell death in cultured neurons\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Thus, we examined whether the microsome fraction from symptomatic \u003cem\u003eTgA53T\u003c/em\u003e mice can induce pathology following BrSt injection.\u003c/p\u003e \u003cp\u003eMicrosomes from pooled BrSt/SpC or CTX from the symptomatic \u003cem\u003eTgA53T\u003c/em\u003e mice were used for BrSt injections of 3\u0026ndash;4 mos old \u003cem\u003eTgA53T\u003c/em\u003e mice. Analysis of the fractions show that pS129αS is enriched in microsomes (P100 or ER) from BrSt/SpC where very little pS129αS is seen in P100 from CTX (Fig.\u0026nbsp;6a). Analysis of organelle markers show that P100 fraction is also enriched in the ER marker (Grp78/BiP). Analysis of injected animals show that P100 from symptomatic \u003cem\u003eTgA53T\u003c/em\u003e mice develop progressive motor abnormalities by ~\u0026thinsp;50 dpi while the animals inoculated with P100 from CTX did not show any disease phenotype (Fig.\u0026nbsp;6b). Significantly, microsome-inoculation leads to onset of motor symptoms much faster than any of the other fractions tested in this study (Compare Figs.\u0026nbsp;1d,5c \u0026amp; 6b), indicating that microsome associated αS oligomer/aggregates are highly pathogenic \u003cem\u003ein vivo\u003c/em\u003e. Neuropathological analysis show that the early motor deficits were indeed associated with significant αS pathology (Fig.\u0026nbsp;6c) with the pattern that is seen with other αS fractions. Collectively, these results provide \u003cem\u003ein vivo\u003c/em\u003e confirmation of highly pathogenic nature of ER-associated αS oligomer/aggregates\u003csup\u003e20,22\u003c/sup\u003e.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this report, we provide a comparative analysis of αS pathology induced by inoculation of lysates from \u003cem\u003eTgA53T\u003c/em\u003e mice. Specifically, we examined the induction of αS pathology as a function of different lysate solubility and location of inoculation. Like that reported with αS PFF models\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, we show that regardless of inoculation site, pathogenic lysates from brains containing α-synucleinopathy lead to a remarkably consistent pattern of ES pathology in the \u003cem\u003eTgA53T\u003c/em\u003e model. This indicates that the regional differences in the vulnerability to develop αS pathology with aging is maintained even when α-synucleinopathy is initiated by inoculation of pathogenic αS species. We also show that, \u003cem\u003ein vivo\u003c/em\u003e, there are multiple αS species with different solubility that induces very similar αS pathologies.\u003c/p\u003e \u003cp\u003eFollowing the creation of the staging hypothesis of PD pathology by Braak and colleagues\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e, series of \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003ein vivo\u003c/em\u003e studies have confirmed that αS pathology can spread from an initial site of αS aggregate induction to other neurons and brain regions\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. It is also established that lysates from murine or human tissues with αS pathology can induce early αS pathology in αS Tg mouse models\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Further, numerous studies have shown that injections of αS PFF into CNS or peripheral tissue can induce αS pathology in both αS Tg mice and wild type mice\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. While studies have generally assumed that the spreading of α-synucleinopathy occurs along the interconnected networks\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e, it is notable that while human α-synucleinopathy may progress rostrally from DMV, the interconnected aspect has not been demonstrated. Further, some studies in rodents have noted deviations from the simple cell-to-cell transmission model\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. In this regard, we also show that while progressive α-synucleinopathy is induced by inoculation with pathogenic αS species, the pattern of α-synucleinopathy following different sites of injections is remarkably consistent with BrSt and SpC neurons being more vulnerable to developing α-synucleinopathy. Our time course study also shows that at intermediate stages, independent of where pathogenic αS is injected, αS pathology is more prominent in BrSt and SpC neurons.\u003c/p\u003e \u003cp\u003eAnalysis of intermediate stage mice for coincidence of αS pathology and glial activation indicates the αS pathology occurs prior to the microglial or astrocyte activation. This result agrees with a prior study demonstrating a temporal relationship between onset of αS pathology and microglial activation following IM inoculation\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e and we have extended prior studies by showing that at even at early stages of αS pathology, there is no obvious glial activation near the αS pathology (Fig.\u0026nbsp;4, S5). Thus, while microglia may promote αS propogation\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e, inflammatory activation of glial cells that can also influence the propagation of αS pathology likely to occur at more advanced stages of αS pathology.\u003c/p\u003e \u003cp\u003eMost \u003cem\u003ein vivo\u003c/em\u003e studies on transmission of α-synucleinopathies have relied on αS PFFs or oligomers derived from recombinant αS as the initiating factor for pathology. Although PFF can efficiently induce pathology, the biological relevance of an \u003cem\u003ein vitro\u003c/em\u003e aggregated recombinant αS is unclear as the structure of αS PFF could be divergent from \u003cem\u003ein vivo\u003c/em\u003e pathology. Because toxic species of αS in human PD and \u003cem\u003ein vivo\u003c/em\u003e models, such as the \u003cem\u003eTgA53T\u003c/em\u003e model, are likely to be a complex mixture of various αS species\u003csup\u003e\u003cspan additionalcitationids=\"CR26\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, characterizing the pathology induced by tissue-derived αS species will have relevance for \u003cem\u003ein vivo\u003c/em\u003e pathogenesis of α-synucleinopathy. This view is supported by differential induction of pathology in huαS Tg models by various human brain derived lysates\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. In \u003cem\u003eTgA53T\u003c/em\u003e models, αS forms soluble oligomers, particularly in the ER, and increasingly aggregate to become insoluble as the disease progresses\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. This, taken together with the fact that pathogenic αS PFF are insoluble, we initially expected that the insoluble fraction from ESL will contain most of the disease initiating activity. Thus, we expected P150, enriched in mature pS129αS containing aggregates, to aggressively induced αS pathology following inoculation. Surprisingly, the S150 from ES mice, despite being biochemically similar to the S150 from AS mice, is capable of inducing αS pathology \u003cem\u003ein vivo\u003c/em\u003e. Although the exact nature of the soluble \u0026ldquo;toxic\u0026rdquo; species is unknown, our results indicate that S150 contains potentially pathogenic FILA1\u0026thinsp;+\u0026thinsp;αS oligomers. Regardless, our results show that different species of αS with varying degrees of solubility can induce identical pattern of pathology. We also show that, consistent with the pathogenic importance of ER associated αS pathology\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e, microsomes from ES \u003cem\u003eTgA53T\u003c/em\u003e mice are highly pathogenic in vivo. These data thus indicate that further separating soluble and insoluble αS species by size and/or subcellular localization could be a fruitful approach for identifying the elusive transmissible αS species.\u003c/p\u003e \u003cp\u003eIn summary, our study indicates that differential neuronal vulnerability contributes to patterns of α-synucleinopathy. Thus, simple spreading of αS pathology via cell-to-cell connection cannot fully account for the progression of α-synucleinopathy. Further, our evidence supports the view that multiple αS species are capable of initiating αS pathology \u003cem\u003ein vivo\u003c/em\u003e and it will be important to fully define the disease relevance of these different pathogenic αS species.\u003c/p\u003e "},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eTransgenic mouse lines\u003c/h2\u003e \u003cp\u003eThe transgenic mouse line over-expressing A53T mutant human αS under control of the mouse prion protein promoter has been described previously (\u003cem\u003eTgA53T\u003c/em\u003e, line G2-3 and line H5)\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. \u003cem\u003eTgA53T(G2-3)\u003c/em\u003e mice used develop a progressive, fatal neurological disease at ~\u0026thinsp;10\u0026ndash;14 months of age and show marked αS pathology by end-stage disease. \u003cem\u003eTgA53T(H5)\u003c/em\u003e line express less αS (~\u0026thinsp;50%) and do not spontaneously develop pathology\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Young, asymptomatic mice aged 3\u0026ndash;6 months were used for all experiments. Animals showing complete hind-limb paralysis are considered end-stage. All study methods were approved in full by the University of Minnesota Institutional Animal Care and Use Committee and were consistent with the National Institutes of Health Office of Laboratory Animal Welfare Policy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eInoculation material\u003c/h2\u003e \u003cp\u003eLysates used for all injections were generated from tissues of \u003cem\u003eTgA53T\u003c/em\u003e mice at either 4 months of age (asymptomatic lysate, ASL) or end-stage (end-stage lysate, ESL). BrSt and spinal cord (SpC) were combined and processed together, as both regions demonstrate robust αS pathology at end-stage\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Preparation of the 3000xg lysate (S3000) has been detailed previously\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Briefly, affected tissue previously harvested and stored at -80\u003cb\u003e\u0026deg;\u003c/b\u003eC was sonicated in sterile saline (0.9% NaCl; 1:10 w/vol). The homogenate was centrifuged for five minutes (3000xg, 4\u003cb\u003e\u0026deg;\u003c/b\u003eC) and the recovered supernatant was the 3000xg lysate (S3000). To obtain highly soluble (S150) and insoluble (P150) fractions, S3000 fraction was centrifuged for 45 minutes (150,000xg, 4\u003cb\u003e\u0026deg;\u003c/b\u003eC). The resulting supernatant was termed the S150 fraction. The pellet was washed and resuspended in sterile saline by sonication (3x10s pulses) in half of the original volume ultracentrifuged and used as the P150 fraction.\u003c/p\u003e \u003cp\u003eEndoplasmic Reticulum (ER)-enriched fractions were obtained from \u003cem\u003eTgA53T\u003c/em\u003e mice as previously detailed\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Briefly, fresh tissues were homogenized in a 1:10 (wt/vol) volume of lysis buffer (250 mM sucrose, 20mM HEPES, 10mM KCl, 1.5mM MgCl\u003csub\u003e2\u003c/sub\u003e, 2 mM EDTA, protease-inhibitor cocktail) and centrifuged at 1,000xg. The supernatant was centrifuged at 10,000xg to pellet mitochondria and the supernatant was centrifuged at 100,000xg to obtain ER (pellet) and cytosol (supernatant).\u003c/p\u003e \u003cp\u003eHuman αS preformed fibrils (PFF) was generated from in vitro aggregation of recombinant wild type human αS monomer as previously described\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Human αS PFF were stored at 5 mg/ml and were sonicated and diluted to desired concentration prior to use.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eInoculation of TgA53T mice\u003c/h2\u003e \u003cp\u003eAll injections were performed unilaterally into the right hemisphere in \u003cem\u003eTgA53T\u003c/em\u003e mice at 3\u0026ndash;6 months of age. Animals were stereotaxically injected with 2.5 \u0026micro;g of total protein in 2.5 \u0026micro;l. The injections occurred at a rate of 0.1 \u0026micro;l per minute using a 28g needle attached via tubing to a Hamilton syringe controlled by a constant pressure syringe pump (Harvard Apparatus, Holliston, MA). The needle was kept in place for five minutes post-injection. The stereotaxic coordinates used for the injection sites were as follows: intracortical/intrastriatal (IC/IS): 2.0 mm lateral from the midline, +\u0026thinsp;0.2 mm relative to bregma, and 0.8 and 2.6 mm deep from the dura; BrSt: 0.2 mm lateral from the midline, -7.34 mm from bregma, 3.75 mm deep from the dura. Intramuscular (IM) injections of αS PFF was done as described \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Briefly, isoflurane anesthetized mice (~\u0026thinsp;3.5 months old) were bilaterally injected into the \u003cem\u003ebicep femoralis\u003c/em\u003e muscle bilaterally with 5 \u0026micro;g of PFF.\u003c/p\u003e \u003cp\u003eStarting at 60 days following PFF injections, the mice were evaluated for disease onset and progression three days per week (Monday, Wednesday, Friday). Disease onset was identified by an imbalance in gait leading to a wobbling phenotype and the end-stage was characterized as complete hindlimb paralysis. Animals were euthanized at either pre-determined time points or upon complete hind-limb paralysis. Half of the brain was used for immunohistochemistry and was immediately drop-fixed in 4% paraformaldehyde and remained in fixative for at least 48 hours. The other half was dissected into gross brain regions, including the cortex and brain stem, and either snap-frozen on dry ice and stored at -80\u003cb\u003e\u0026deg;\u003c/b\u003eC or processed immediately. Half of spinal cords collected remained in the spinal column and were drop-fixed in 4% paraformaldehyde and half were removed and frozen or processed in the same manner as the brains.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eImmunohistochemistry and mapping of αS pathology\u003c/h2\u003e \u003cp\u003eAll fixed brains were embedded in paraffin and serially sectioned (6 \u0026micro;m) in the sagittal plane. Four to Six sections taken every 12th section, starting at first section from midline containing hippocampus, was processed using standard immunohistochemical (IHC) techniques for DAB (Covance) detection as previously described\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Sections were counterstained with hematoxylin and imaged with a Leica DM2500 microscope using Leica Application Suite v4.1 imaging software. PhosphoSerine-129 αS (pS129αS) positive inclusions/cell bodies and neurites were mapped at three lateral positions: 0.225, 1.10, and 1.525 mm from the midline using Image J/Fiji (NIH) as previously described \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eImmunofluorescence staining\u003c/h2\u003e \u003cp\u003eParaffin sections of sagittal brain (BrSt injected) and SpC (IM injected) were processed for immunofluorescent staining as previously described\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Briefly, the tissues were first deparaffinized followed by 30 minutes of antigen retrieval. 3% hydrogen peroxide was used to quench endogenous peroxidases followed by blocking using 100% background sniper solution for 13 minutes. Sections were then incubated in primary antibodies with 5% sniper diluted in TRIS overnight at 4\u003csup\u003eo\u003c/sup\u003eC (pS129αS, Wako, 015-25191, 1:500; Iba1, Wako, 019-19741, 1:100; GFAP, Dako Cytomation, Z0334, 1:200) followed by incubation in secondary fluorophore conjugated antibody (Donkey anti-mouse 488, Donkey anti-rabbit 594). Sections were imaged using a Leica Stellaris 8 confocal microscope.\u003c/p\u003e \u003cp\u003e \u003cem\u003eWestern blot (immunoblot) analysis.\u003c/em\u003e \u003c/p\u003e \u003cp\u003eLysate preparation and immunoblot analysis were performed as previously described\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Briefly, brain tissue from mice were dissected and stored at -80\u0026deg;C and frozen tissues were homogenized in TNE buffer [Tris-HCl 50 mM, NaCl 150 mM and EDTA 5 mM, and protease and phosphatase inhibitors (HALT; Thermo-Fisher; Waltham, MA)]. To obtain total lysate, homogenates were solubilized with 0.5% NP40, 0.5% DOC, and 1% SDS. For TX-100 non-ionic detergent fractionation, TNE homogenates were added to 1% TX-100 and sonicated prior to centrifugation at 100,000xg for 20 min. Supernatant was collected as the soluble fraction while the pellet was washed and centrifuged again in 1% TX-100. The resulting pellet was then reconstituted in TNE with detergents as the TX-100 insoluble fraction\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe protein content of the lysates were determined using the BCA assay (Pierce, Thermo; Rockford, IL) and samples were prepared to equal protein concentrations in reducing, SDS-sample, Laemmli buffer (Boston BioProducts; Ashland, MA). For Western blot analysis, protein lysates were run on Criterion\u0026trade; TGX\u0026trade; gels (BioRad, Hercules, CA) and transferred onto nitrocellulose membranes. Proteins on membranes were detected using appropriate primary antibodies followed by horseradish peroxidase \u003cb\u003e(\u003c/b\u003eHRP)-conjugated secondary antibodies (Invitrogen, Carlsbad, CA). Membranes were then developed using chemiluminescent substrates (BioRad and Thermo) and imaged using the ImageQuant LAS 4000 detection system (GE Life Sciences, Piscataway, NJ). Densitometry on Western blot images was analyzed using the ImageQuant TL 8.1 software (GE Life Sciences).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eAntibodies\u003c/h2\u003e \u003cp\u003ePrimary antibodies used for immunohistochemistry and immunoblots are listed in Supplemental Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eAll analyses were done using GraphPad Prism. Values are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD/SEM as indicated. Differences between means were analyzed by Student\u0026rsquo;s \u003cem\u003et\u003c/em\u003e-test, one-way ANOVA, or two-way ANOVA. ANOVA analyses were combined with the Tukey post-hoc test for multiple comparisons (Prism; Graph Pad Software). Log-rank (Mantel-Cox) test was used to assess significant differences in survival curves. An α value of 0.05 and adjusted \u003cem\u003eP\u003c/em\u003e values for multiple comparisons were used to determine significance.\u003c/p\u003e \u003c/div\u003e "},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contributions:\u003c/h2\u003e \u003cp\u003eJ.B. and M.K.L. conceived and designed the study. All authors were responsible for the acquisition of the data. J.B. S.C.V. and M.K.L. were responsible for data analysis and writing/editing of the manuscript.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCompeting Interest:\u003c/strong\u003e \u003cp\u003eAuthors declare no competing financial or non-financial interests.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAcknowledgements:\u003c/h2\u003e \u003cp\u003eThis work was funded by Grants R01 NS086074, R01 NS092093, and ASAP-024407. ASAP-02447 is administered by Michael J. Fox Foundation (MJFF) on the behalf of the Aligning Science Across Parkinson's (ASAP) initiative. We thank Cindy Croy for help in generating the transgenic mouse cohorts and Dr. Poul Henning Jensen, Aarhus University for sharing the FILA-1 antibody.\u003c/p\u003e\n\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eData Availability:\u003c/h2\u003e \u003cp\u003eThe datasets and images used and/or analyzed for the current study are available from the corresponding author on reasonable request.\u003c/p\u003e \u003c/div\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eVila, M. \u0026amp; Przedborski, S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 10 Suppl, S58\u0026ndash;62 (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eObeso, J.A. \u003cem\u003eet al.\u003c/em\u003e Missing pieces in the Parkinson's disease puzzle. \u003cem\u003eNat Med\u003c/em\u003e 16, 653\u0026thinsp;\u0026ndash;\u0026thinsp;61 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBraak, H. \u003cem\u003eet al.\u003c/em\u003e Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197\u0026ndash;211 (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, J.Y. \u003cem\u003eet al.\u003c/em\u003e Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14, 501\u0026ndash;3 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. \u0026amp; Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14, 504\u0026ndash;6 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuk, K.C. \u003cem\u003eet al.\u003c/em\u003e Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209, 975\u0026ndash;86 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChung, H.K., Ho, H.A., Perez-Acuna, D. \u0026amp; Lee, S.J. Modeling alpha-Synuclein Propagation with Preformed Fibril Injections. J Mov Disord 12, 139\u0026ndash;151 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee, M.K. \u003cem\u003eet al.\u003c/em\u003e Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --\u0026gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99, 8968\u0026ndash;73 (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVermilyea, S.C. \u003cem\u003eet al.\u003c/em\u003e Loss of tau expression attenuates neurodegeneration associated with alpha-synucleinopathy. Transl Neurodegener 11, 34 (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBraak, H. \u003cem\u003eet al.\u003c/em\u003e Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). \u003cem\u003eJ Neurol\u003c/em\u003e 249 Suppl 3, III/1\u0026ndash;5 (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKarim, M.R. \u003cem\u003eet al.\u003c/em\u003e alpha-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener 15, 27 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTeravskis, P.J. \u003cem\u003eet al.\u003c/em\u003e A53T mutant alpha-synuclein induces tau dependent postsynaptic impairment independent of neurodegenerative changes. J Neurosci (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eColla, E. \u003cem\u003eet al.\u003c/em\u003e Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha-Synucleinopathy In Vivo. J Neurosci 32, 3306\u0026ndash;20 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGeorge, S. \u003cem\u003eet al.\u003c/em\u003e Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease. Mol Neurodegener 14, 34 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSorrentino, Z.A. \u003cem\u003eet al.\u003c/em\u003e Intrastriatal injection of alpha-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol Neurodegener 12, 40 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSorrentino, Z.A., Giasson, B.I. \u0026amp; Chakrabarty, P. alpha-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol 138, 1\u0026ndash;21 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNanclares, C. \u003cem\u003eet al.\u003c/em\u003e Dysregulation of astrocytic Ca(2+) signaling and gliotransmitter release in mouse models of alpha-synucleinopathies. Acta Neuropathol 145, 597\u0026ndash;610 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSorrentino, Z.A. \u003cem\u003eet al.\u003c/em\u003e Motor neuron loss and neuroinflammation in a model of alpha-synuclein-induced neurodegeneration. Neurobiol Dis 120, 98\u0026ndash;106 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLindersson, E. \u003cem\u003eet al.\u003c/em\u003e Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279, 12924\u0026ndash;34 (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eColla, E. \u003cem\u003eet al.\u003c/em\u003e Accumulation of Toxic alpha-Synuclein Oligomer within Endoplasmic Reticulum Occurs in alpha-Synucleinopathy In Vivo. J Neurosci 32, 3301\u0026ndash;5 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKayed, R. \u003cem\u003eet al.\u003c/em\u003e Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eColla, E. \u003cem\u003eet al.\u003c/em\u003e Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. Neurobiology of Disease 111, 36\u0026ndash;47 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKillinger, B.A. \u0026amp; Kordower, J.H. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem 150, 605\u0026ndash;611 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThi Lai, T. \u003cem\u003eet al.\u003c/em\u003e Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson's disease mouse model. NPJ Parkinsons Dis 10, 32 (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, W. \u003cem\u003eet al.\u003c/em\u003e Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102, 2162\u0026ndash;7 (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSonustun, B. \u003cem\u003eet al.\u003c/em\u003e Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy. \u003cem\u003eCells\u003c/em\u003e 11(2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, S. \u003cem\u003eet al.\u003c/em\u003e Post-translational modifications of soluble alpha-synuclein regulate the amplification of pathological alpha-synuclein. Nat Neurosci 26, 213\u0026ndash;225 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLloyd, G.M. \u003cem\u003eet al.\u003c/em\u003e Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human alpha-synuclein transgenic mice. Acta Neuropathol 143, 663\u0026ndash;685 (2022).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-3982325/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3982325/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003ePathological aggregation of a-synuclein (aS) is implicated in the pathogenesis of Parkinson’s disease (PD) and other a-synucleinopathies. The current view is that neuron-to-neuron spreading of aS pathology contributes to the progression of a-synucleinopathy. We used an A53T mutant human aS transgenic mouse model (\u003cem\u003eTgA53T\u003c/em\u003e) to examine whether the site of pathogenic aS inoculation affects the pattern of neuropathology and whether soluble and insoluble fractions derived from crude pathogenic tissue lysates exhibit differential capacities to initiate aS pathology. To test whether the inoculation site impacts the ultimate spatial/temporal patterns of aS pathology, aS preformed fibrils (PFF), or brain homogenates from \u003cem\u003eTgA53T\u003c/em\u003e mice with a-synucleinopathy, were injected into the cortex/striatum, brain stem, or skeletal muscle. In all cases, inoculation of pathogenic aS induced end-stage motor dysfunction within ~100 days post-inoculation (dpi). Significantly, irrespective of the inoculation sites, ultimate distribution of the aS pathology was like that seen in normally aged \u003cem\u003eTgA53T\u003c/em\u003e mice at end-stage, indicating that the intrinsic neuronal vulnerability is a significant determinant in the induction of aS pathology, even when initiated by inoculation of pathogenic aS. Temporal analysis of brain stem injected \u003cem\u003eTgA53T\u003c/em\u003e mice show that initial aS pathology was seen by 30 days post-inoculation and inflammatory changes occur at later stages. To determine if the aS species with differential solubility are differentially pathogenic, brain lysates from end-stage \u003cem\u003eTgA53T\u003c/em\u003emice were fractionated into highly soluble (S150) and insoluble (P150) fractions, as well as the endoplasmic reticulum (ER)-enriched fraction (P100). Significantly, all fractions were able to seed \u003cem\u003ede novo\u003c/em\u003e aS pathology \u003cem\u003ein vivo\u003c/em\u003e, when injected unilaterally into \u003cem\u003eTgA53T\u003c/em\u003emice with the ER fractions being most pathogenic. Our results suggest that multiple aS species from brain can initiate the development of progressive aS pathology.\u003c/p\u003e","manuscriptTitle":"Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-05 16:40:23","doi":"10.21203/rs.3.rs-3982325/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"706ceba5-5728-43fe-8c45-7bb25cc6fb5d","owner":[],"postedDate":"March 5th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":29084113,"name":"Biological sciences/Neuroscience/Diseases of the nervous system/Parkinson's disease"},{"id":29084114,"name":"Biological sciences/Neuroscience/Diseases of the nervous system/Neurodegeneration"}],"tags":[],"updatedAt":"2025-07-02T15:08:05+00:00","versionOfRecord":{"articleIdentity":"rs-3982325","link":"https://doi.org/10.3390/ijms26136254","journal":{"identity":"international-journal-of-molecular-sciences","isVorOnly":true,"title":"International Journal of Molecular Sciences"},"publishedOn":"2025-06-28 00:00:00","publishedOnDateReadable":"June 28th, 2025"},"versionCreatedAt":"2024-03-05 16:40:23","video":"","vorDoi":"10.3390/ijms26136254","vorDoiUrl":"https://doi.org/10.3390/ijms26136254","workflowStages":[]},"version":"v1","identity":"rs-3982325","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3982325","identity":"rs-3982325","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}